<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6471205</article-id><article-id pub-id-type="pmcid-ver">PMC6471205.1</article-id><article-id pub-id-type="pmcaid">6471205</article-id><article-id pub-id-type="pmcaiid">6471205</article-id><article-id pub-id-type="pmid">30866479</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics11030110</article-id><article-id pub-id-type="publisher-id">pharmaceutics-11-00110</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="H">Hua</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-11-00110">1</xref><xref ref-type="aff" rid="af2-pharmaceutics-11-00110">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5085-0682</contrib-id><name name-style="western"><surname>Yuan</surname><given-names initials="D">Dongfen</given-names></name><xref ref-type="aff" rid="af2-pharmaceutics-11-00110">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="Y">Yun</given-names></name><xref ref-type="aff" rid="af3-pharmaceutics-11-00110">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3974-9073</contrib-id><name name-style="western"><surname>Cao</surname><given-names initials="Y">Yanguang</given-names></name><xref ref-type="aff" rid="af2-pharmaceutics-11-00110">2</xref><xref ref-type="aff" rid="af4-pharmaceutics-11-00110">4</xref><xref rid="c1-pharmaceutics-11-00110" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pharmaceutics-11-00110"><label>1</label>Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China; <email>huahe827@163.com</email></aff><aff id="af2-pharmaceutics-11-00110"><label>2</label>Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; <email>dyuan@email.unc.edu</email></aff><aff id="af3-pharmaceutics-11-00110"><label>3</label>Department of Biomedical Engineering, University at Buffalo, The State University of New York, 332 Bonner Hall, Buffalo, NY 14260, USA; <email>ywu32@buffalo.edu</email></aff><aff id="af4-pharmaceutics-11-00110"><label>4</label>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA</aff><author-notes><corresp id="c1-pharmaceutics-11-00110"><label>*</label>Correspondence: <email>yanguang@unc.edu</email>; Tel.: +1-(919)-966-4040</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>3</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2019</year></pub-date><volume>11</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">332967</issue-id><elocation-id>110</elocation-id><history><date date-type="received"><day>30</day><month>1</month><year>2019</year></date><date date-type="accepted"><day>28</day><month>2</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>27</day><month>04</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-05 16:25:10.543"><day>05</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-11-00110.pdf"/><abstract><p>Liposomal formulations have been developed to improve the therapeutic index of encapsulated drugs by altering the balance of on- and off-targeted distribution. The improved therapeutic efficacy of liposomal drugs is primarily attributed to enhanced distribution at the sites of action. The targeted distribution of liposomal drugs depends not only on the physicochemical properties of the liposomes, but also on multiple components of the biological system. Pharmacokinetic&#8211;pharmacodynamic (PK&#8211;PD) modeling has recently emerged as a useful tool with which to assess the impact of formulation- and system-specific factors on the targeted disposition and therapeutic efficacy of liposomal drugs. The use of PK&#8211;PD modeling to facilitate the development and regulatory reviews of generic versions of liposomal drugs recently drew the attention of the U.S. Food and Drug Administration. The present review summarizes the physiological factors that affect the targeted delivery of liposomal drugs, challenges that influence the development and regulation of liposomal drugs, and the application of PK&#8211;PD modeling and simulation systems to address these challenges.</p></abstract><kwd-group><kwd>pharmacokinetic&#8211;pharmacodynamics</kwd><kwd>modeling and simulation</kwd><kwd>PBPK model</kwd><kwd>liposomal drugs</kwd><kwd>EPR effect</kwd><kwd>regulatory review</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-11-00110"><title>1. Introduction</title><p>Liposomes were first described by British hematologist, Alec Bangham, in 1961 [<xref rid="B1-pharmaceutics-11-00110" ref-type="bibr">1</xref>]. Shortly thereafter, the concept of liposomal drug delivery systems rapidly gained popularity [<xref rid="B2-pharmaceutics-11-00110" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-11-00110" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-11-00110" ref-type="bibr">4</xref>]. Liposomes are spherical vesicles that comprise one or more phospholipid bilayers. They are used to improve the solubility, bioavailability, systemic retention, or tissue-related distribution of encapsulated drugs [<xref rid="B3-pharmaceutics-11-00110" ref-type="bibr">3</xref>,<xref rid="B5-pharmaceutics-11-00110" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-11-00110" ref-type="bibr">6</xref>].</p><p>By increasing on-target drug accumulation and lowering off-target drug distribution, liposome-based delivery systems have the ability to significantly widen the therapeutic window. In particular, liposomes have been demonstrated to constitute an effective drug delivery system in oncology as they have the capacity to selectively deliver cytotoxic drugs to solid tumors [<xref rid="B7-pharmaceutics-11-00110" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-11-00110" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-11-00110" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceutics-11-00110" ref-type="bibr">10</xref>]. Maeda et al. suggested that enhanced permeability and retention (EPR) were fundamental to the increased delivery of drugs by liposomes to the tumor [<xref rid="B11-pharmaceutics-11-00110" ref-type="bibr">11</xref>]. The EPR effect is based on observations that tumor tissues often have an abnormal tumor vasculature, an aberrant vascular architecture, and a lack of lymphatic drainage [<xref rid="B12-pharmaceutics-11-00110" ref-type="bibr">12</xref>]. In 1995, the first liposomal drug, Doxil<sup>&#174;</sup>, was approved by the U.S. Food and Drug Administration (FDA) to treat ovarian cancer and acquired immune deficiency syndrome-related Kaposi&#8217;s sarcoma [<xref rid="B13-pharmaceutics-11-00110" ref-type="bibr">13</xref>]. Investment in the development of liposomal drugs has grown exponentially over the past two decades. A number of strategies have been proposed to further optimize liposome delivery systems [<xref rid="B14-pharmaceutics-11-00110" ref-type="bibr">14</xref>]. By 2018, a total of 16 liposomal drugs had been approved by the FDA and/or European Medicines Agency (EMA).</p><p>The physicochemical properties of liposomes, including size, surface charge, shape, and surface coating, can be potentially engineered to improve the targeted delivery and enhance the pharmacological efficacy of encapsulated drugs, making liposomes a versatile delivery system [<xref rid="B15-pharmaceutics-11-00110" ref-type="bibr">15</xref>]. The multifunctionality of liposomes provides a broad design space in which to improve drug delivery efficiency. However, it often results in intricate interactions with multiple components of the biological system, leading to varying in vivo disposition behaviors, when compared to their small molecule counterparts. Considerable effort has been made in trying to establish a quantitative relationship between the physicochemical properties of liposomes and related in vivo disposition behavior. Nevertheless, the ability to accurately predict the disposition characteristics and biological interactions of liposomes based on their physicochemical properties has generally remained unattainable. The dynamic nature of the biological system and the multiple biological components that are involved in interactions with liposomes makes it challenging to predict the in vivo disposition of liposomal drugs.</p><p>Pharmacokinetic&#8211;pharmacodynamic (PK&#8211;PD) modeling and simulation is widely applied in drug development and regulation systems. Applications include the translation of preclinical observations to the clinical setting, the selection of dosing regimens in special populations, and the optimization of clinical trials [<xref rid="B16-pharmaceutics-11-00110" ref-type="bibr">16</xref>]. PK&#8211;PD modeling and simulation systems are a systems-based approach that enables the joint analysis of system- and drug-specific factors and has shown significant potential in identifying the multiscale mechanisms of liposomal disposition, quantifying and optimizing delivery systems, and correlating the physicochemical properties with systemic performance [<xref rid="B17-pharmaceutics-11-00110" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-11-00110" ref-type="bibr">18</xref>].</p><p>The current developmental landscape of liposomal drugs, with a special focus on PK&#8211;PD properties, is evaluated in this paper. The biophysical barriers to targeted drug delivery using liposomes are reviewed, in keeping with the challenges associated with liposomal drug development and the regulatory assessment. In particular, PK&#8211;PD modeling and simulation systems are investigated as a way of addressing these challenges.</p></sec><sec id="sec2-pharmaceutics-11-00110"><title>2. Liposomal Drugs Approved for Use in Humans</title><p>Since the first liposomal drug, Doxil<sup>&#174;</sup>, was endorsed in 1995, 16 liposomal drugs have been approved for human use. Most liposomal drugs are indicated for cancer therapy (<xref rid="pharmaceutics-11-00110-t001" ref-type="table">Table 1</xref>), as per the EPR hypothesis. Many liposomes have also been developed for the delivery of anti-infective drugs, vaccines, analgesics, and photodynamic therapeutic agents. Bulbake et al. listed the liposomes that have been approved for use in humans in their review [<xref rid="B14-pharmaceutics-11-00110" ref-type="bibr">14</xref>]. The PK&#8211;PD profiles of the approved liposomal drugs were the focus of the current research.</p><sec id="sec2dot1-pharmaceutics-11-00110"><title>2.1. Liposomal Drugs for Cancer Treatment</title><p>Doxorubicin is one of the most effective anti-cancer drugs used to treat a broad range of cancers [<xref rid="B19-pharmaceutics-11-00110" ref-type="bibr">19</xref>]. However, accumulative dose-related cardiotoxicity drastically restricts its clinical application [<xref rid="B20-pharmaceutics-11-00110" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-11-00110" ref-type="bibr">21</xref>]. Thus, liposomes were developed to improve the therapeutic index of doxorubicin by selectively delivering it to tumors, while reducing its accumulation in the heart. Currently, two types of liposomal doxorubicin, i.e., Doxil<sup>&#174;</sup> (or Caelyx<sup>&#174;</sup> in Europe) and Myocet<sup>&#174;</sup>, have been approved for clinical use. The surface modification of liposomes with polyethylene glycol (PEG) is the major difference between them [<xref rid="B22-pharmaceutics-11-00110" ref-type="bibr">22</xref>]. Doxil<sup>&#174;</sup> (Caelyx<sup>&#174;</sup>), pegylated liposomal doxorubicin, was the first liposomal drug approved by the FDA. Myocet<sup>&#174;</sup>, non-pegylated liposomal doxorubicin, is currently licensed in Europe and Canada. The encapsulation of doxorubicin in these two types of liposomes remarkably changes the PK profile and tissue distribution of doxorubicin. In studies on humans, the volume of distribution decreased from 254 L to 142 L or to 4 L, and systemic clearance was reduced from 45 L/hour to 9.7 L/hour or to 0.1 L/hour for Myocet<sup>&#174;</sup> and Doxil, respectively [<xref rid="B23-pharmaceutics-11-00110" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-11-00110" ref-type="bibr">24</xref>]. Liposomal doxorubicin accumulation in the targeted tumors was reported to be 4~16-fold higher than free doxorubicin accumulation [<xref rid="B23-pharmaceutics-11-00110" ref-type="bibr">23</xref>]. Importantly, both Doxil<sup>&#174;</sup> and Myocet<sup>&#174;</sup> substantially reduced cardiotoxicity [<xref rid="B25-pharmaceutics-11-00110" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-11-00110" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-11-00110" ref-type="bibr">27</xref>]. Despite the improvement in disposition profiles, only a moderate increase in patient survival benefit was seen with the use of both liposomal delivery systems for doxorubicin, suggesting that a large gap remains in the translation of targeted delivery to improved clinical outcomes [<xref rid="B26-pharmaceutics-11-00110" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-11-00110" ref-type="bibr">27</xref>].</p><p>Apart from Doxil<sup>&#174;</sup> and Myocet<sup>&#174;</sup>, Lipodox<sup>&#174;</sup>, a generic form of Doxil<sup>&#174;</sup>, gained expedited approval in 2012 in response to a drug shortage of Doxil<sup>&#174;</sup> in the United States. However, by early 2019, Lipodox<sup>&#174;</sup> had not yet been approved by the EMA. PK equivalence (between Doxil<sup>&#174;</sup> and Lipodox<sup>&#174;</sup>) was evaluated in two clinical studies. Bioequivalence was concluded for total and encapsulated doxorubicin in both trials. However, bioequivalence was only concluded in one trial for free doxorubicin and the other trial concluded that there was nonequivalence due to the small sample size [<xref rid="B28-pharmaceutics-11-00110" ref-type="bibr">28</xref>]. The plasma drug concentration, a conventional surrogate for small molecules in bioequivalence studies, does not necessarily reflect the bioavailability of the liposomal drug in the intended targeted organ, nor the therapeutic benefit of generic liposomes [<xref rid="B29-pharmaceutics-11-00110" ref-type="bibr">29</xref>]. The therapeutic equivalence of LipoDox<sup>&#174;</sup> and Doxil<sup>&#174;</sup> continues to be debated. Both equivalence and nonequivalence data have been reported in animal models [<xref rid="B30-pharmaceutics-11-00110" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-11-00110" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-11-00110" ref-type="bibr">32</xref>].</p><p>Daunorubicin is an anthracycline compound that is primarily used to treat acute myeloid leukemia. Liposomal daunorubicin (DaunoXome<sup>&#174;</sup>) was approved by the FDA in 1996 to treat human immunodeficiency virus-associated Kaposi&#8217;s sarcoma [<xref rid="B33-pharmaceutics-11-00110" ref-type="bibr">33</xref>]. Liposomal daunorubicin was shown to increase daunorubicin accumulation in the tumor by approximately 10-fold in mice [<xref rid="B34-pharmaceutics-11-00110" ref-type="bibr">34</xref>]. In humans, liposomal daunorubicin was found to significantly prolong systemic retention and increase the targeted exposure of liposomal daunorubicin in comparison to the free drug [<xref rid="B35-pharmaceutics-11-00110" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-11-00110" ref-type="bibr">36</xref>].</p><p>The combination of cytarabine/daunorubicin at a fixed molar ratio of 5:1 was optimized to exert a synergistic effect in killing the P388 leukemic cell line in vitro [<xref rid="B37-pharmaceutics-11-00110" ref-type="bibr">37</xref>]. Vyxeos<sup>&#174;</sup>, a liposomal drug, was designed to simultaneously deliver cytarabine/daunorubicin at a fixed molar ratio of 5:1 [<xref rid="B37-pharmaceutics-11-00110" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-11-00110" ref-type="bibr">38</xref>]. Vyxeos<sup>&#174;</sup> was approved in 2017 by the FDA to treat newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes in adults [<xref rid="B39-pharmaceutics-11-00110" ref-type="bibr">39</xref>]. In a preclinical study, Vyxeos<sup>&#174;</sup> was demonstrated to selectively increase the exposure of daunorubicin and cytarabine in a fixed ratio in leukemia-laden bone marrow, thus resulting in a significantly prolonged effect with regard to leukemia suppression [<xref rid="B40-pharmaceutics-11-00110" ref-type="bibr">40</xref>]. In clinical trials, it was shown to have superior efficacy and comparable toxicity to the standard combination of daunorubicin and cytarabine in patients with AML [<xref rid="B41-pharmaceutics-11-00110" ref-type="bibr">41</xref>].</p><p>Both vincristine and cytarabine are cell cycle phase-specific chemotherapeutic agents. Prolonged exposure to tumors above a threshold of effective concentration is critical to ensure their therapeutic efficacy. Free forms of vincristine and cytarabine are hardly able to maintain the therapeutic concentration owing to rapid clearance [<xref rid="B42-pharmaceutics-11-00110" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-11-00110" ref-type="bibr">43</xref>]. Thus, prolonging systemic retention is a strategy that can be used to increase their efficacy.</p><p>DepoCyt<sup>&#174;</sup> is a liposomal cytarabine that was developed using DepoFoam<sup>&#8482;</sup> technology [<xref rid="B44-pharmaceutics-11-00110" ref-type="bibr">44</xref>]. DepoCyt<sup>&#174;</sup> was approved by the FDA in 1999 to treat lymphomatous meningitis. The slow and continuous release profile of liposome resulted in extended (i.e., up to 14 days) and enhanced tumor exposure to cytarabine, thus increasing the response rate when compared with the free cytarabine treatment [<xref rid="B45-pharmaceutics-11-00110" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-11-00110" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-11-00110" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-11-00110" ref-type="bibr">48</xref>]. Marqibo<sup>&#174;</sup> is a liposomal vincristine injection that was approved to treat adults with Philadelphia chromosome-negative acute lymphoblastic leukemia [<xref rid="B48-pharmaceutics-11-00110" ref-type="bibr">48</xref>]. It was designed to gradually release vincristine in the targeted tumors and prolong exposure, with the objective of increasing therapeutic efficacy [<xref rid="B49-pharmaceutics-11-00110" ref-type="bibr">49</xref>]. Compared to its free counterpart, liposomal vincristine was shown to have lower dose-limiting toxicity and the ability to be administered at higher doses [<xref rid="B50-pharmaceutics-11-00110" ref-type="bibr">50</xref>]. Marqibo<sup>&#174;</sup> demonstrated promising antitumor activity in adult patients with refractory or relapsed acute lymphoblastic leukemia in a phase II study, thus ensuring its accelerated approval in 2012 [<xref rid="B51-pharmaceutics-11-00110" ref-type="bibr">51</xref>].</p><p>Muramyl tripeptide phosphatidylethanolamine (MTP-PE), an immunotherapeutic agent, is known to activate macrophages and monocytes in the mononuclear phagocyte system (MPS), including in the liver, spleen, and lungs [<xref rid="B52-pharmaceutics-11-00110" ref-type="bibr">52</xref>]. Mepact<sup>&#174;</sup>, liposomal MTP-PE, was approved by the EMA as an &#8220;orphan&#8221; drug in 2004, for use in combination with postoperative multiagent chemotherapy to treat high-grade, resectable, nonmetastatic bone tumors. Liposome-encapsulated MTP-PE was selectively delivered to the MPS. It was shown to be retained in the targeted organs for a long duration [<xref rid="B53-pharmaceutics-11-00110" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceutics-11-00110" ref-type="bibr">54</xref>]. In addition to having an improved biodistribution profile, MTP-PE demonstrated high therapeutic efficacy and low off-target toxicity [<xref rid="B55-pharmaceutics-11-00110" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-11-00110" ref-type="bibr">56</xref>].</p><p>Onivyde<sup>&#8482;</sup> is an irinotecan liposomal injection that is used to treat patients with metastatic pancreatic adenocarcinoma. Liposomal irinotecan was associated with delayed clearance and had a prolonged half-life and reduced volume of distribution in a phase I clinical trial [<xref rid="B57-pharmaceutics-11-00110" ref-type="bibr">57</xref>]. Compared to free irinotecan, liposomal irinotecan reduced the plasma peak concentration, had a prolonged terminal half-life, and increased the plasma exposure of SN-38, a bioactive metabolite of irinotecan [<xref rid="B57-pharmaceutics-11-00110" ref-type="bibr">57</xref>]. It was approved in 2015 by the FDA for intended use in combination with fluorouracil and folinic acid, based in part on its prolonged progression-free and overall survival in the nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1) study [<xref rid="B58-pharmaceutics-11-00110" ref-type="bibr">58</xref>].</p></sec><sec id="sec2dot2-pharmaceutics-11-00110"><title>2.2. Liposomal Drugs for Other Indications</title><p>Initially, amphotericin B was a widely used antifungal agent in the management of severe systemic fungal infections. However, it was discontinued primarily as a result of dose-limiting toxicity, including nephrotoxicity and infusion-related reactions [<xref rid="B59-pharmaceutics-11-00110" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceutics-11-00110" ref-type="bibr">60</xref>]. Liposomal amphotericin B (Ambisome<sup>&#174;</sup>) was developed in 1997 to treat a broad range of fungal infections. Amphotericin B is encapsulated in the liposome bilayer and is only released when the liposome binds to the fungus [<xref rid="B60-pharmaceutics-11-00110" ref-type="bibr">60</xref>]. This liposome formulation significantly improves the safety profile owing to the relatively low concentration of amphotericin B that is released into the blood circulation [<xref rid="B61-pharmaceutics-11-00110" ref-type="bibr">61</xref>].</p><p>A liposomal amikacin inhalation suspension (Arikayce<sup>&#174;</sup>) was recently approved to treat <italic toggle="yes">Mycobacterium avium complex</italic> lung disease. When treating lung infections, it is difficult to deliver an adequate amount of antibiotic to the lung while maintaining nontoxic plasma concentrations. Arikayce<sup>&#174;</sup> was designed to overcome this challenge via the delivery of a high liposomal antibiotic load to the lungs after nebulization [<xref rid="B62-pharmaceutics-11-00110" ref-type="bibr">62</xref>]. Compared to intravenously delivered free amikacin, Arikayce<sup>&#174;</sup> was shown to respectively increase exposure to amikacin by 42-, 69-, and 274-fold in the lung tissues, airways, and macrophages [<xref rid="B62-pharmaceutics-11-00110" ref-type="bibr">62</xref>]. The drug concentration of Arikayce<sup>&#174;</sup> in the pulmonary macrophages increased by 5~8-fold, when compared to inhaled free amikacin [<xref rid="B62-pharmaceutics-11-00110" ref-type="bibr">62</xref>].</p><p>Epaxal<sup>&#174;</sup> is a virosome-based vaccine that is used to ensure the prevention of hepatitis A [<xref rid="B63-pharmaceutics-11-00110" ref-type="bibr">63</xref>]. Deactivated hepatitis A is attached to the virosome surface. The Epaxal<sup>&#174;</sup> structure promotes the delivery of the hepatitis A virus antigen to the immunocompetent cells. Compared to conventional aluminum-adsorbed vaccines, Epaxal<sup>&#174;</sup> confers higher tolerability and fewer adverse effects.</p><p>Inflexal<sup>&#174;</sup> V is a virosomal-adjuvanted, inactivated influenza vaccine. The hemagglutinin is extracted from the influenza virus and is incorporated into the liposomal membranes. In one study, Inflexal<sup>&#174;</sup> V was shown to have a superior immune response compared to other vaccines, such as commercially available whole-virus and subunit vaccines [<xref rid="B64-pharmaceutics-11-00110" ref-type="bibr">64</xref>]. Limited PK profiles have been reported for liposomal vaccines.</p><p>DepoDur<sup>&#8482;</sup> is an extended-release epidural morphine that was approved in 2004 to manage postsurgical pain. Morphine is encapsulated in lipid foam using DepoFoam<sup>&#8482;</sup> technology [<xref rid="B65-pharmaceutics-11-00110" ref-type="bibr">65</xref>] to allow its extended release into the epidural space. The maximal morphine concentration in the serum and cerebrospinal fluid was found to be 6% and 32% of that for a dose of morphine sulfate, respectively, after the epidural administration of a single dose of DepoDur<sup>&#8482;</sup> [<xref rid="B66-pharmaceutics-11-00110" ref-type="bibr">66</xref>]. The pain relief associated with DepoDur<sup>&#8482;</sup> is prolonged, while the supraspinal toxic effect is reduced compared to morphine sulfate, likely due to the sustained release of morphine. Exparel<sup>&#174;</sup> is a bupivacaine extended-release liposome that was approved in 2011 to treat postsurgical pain. Similar to DepoDur<sup>&#8482;</sup> and DepoCyt<sup>&#174;</sup>, it is also a DepoFoam<sup>&#8482;</sup> technology-based liposome. Compared to the plain formulation, the peak concentrations of bupivacaine for liposomal bupivacaine were comparable (0.87 vs. 0.83 &#956;g/mL) at a 4-fold higher dose, and the time to maximal concentration was 7-fold greater [<xref rid="B67-pharmaceutics-11-00110" ref-type="bibr">67</xref>], resulting in a lower risk of toxicity. The expanded safe dose range and the delayed elimination of bupivacaine in the liposome formulation produce prolonged analgesia.</p><p>Visudyne<sup>&#174;</sup> is a light-activated drug that was approved to treat patients with age-related macular degeneration-induced neovascularization. Verteporfin was encapsulated in liposomes and utilized as a photosensitizer in photodynamic therapy to selectively eradicate abnormal blood vessels in the eye. The therapeutic benefits of liposomal verteporfin can last for at least 24 months without safety-related challenges when treating age-related macular degeneration [<xref rid="B68-pharmaceutics-11-00110" ref-type="bibr">68</xref>]. The systemic clearance of verteporfin was not seen to be significantly influenced by the liposome formulation in a biodistribution study [<xref rid="B69-pharmaceutics-11-00110" ref-type="bibr">69</xref>]. The liposome formulation slightly increased the distribution of verteporfin in the tissues and tumor.</p></sec></sec><sec id="sec3-pharmaceutics-11-00110"><title>3. Physiological Barriers to the Targeted Delivery of Liposomes</title><p>The pharmacological effects of chemical compounds are usually limited by their poor physicochemical and PK properties, such as low solubility, suboptimal biodistribution, and rapid clearance. Liposomes are designed to overcome these challenges through the encapsulation of chemical compounds, thereby increasing drug solubility, reducing systemic clearance, and improving drug distribution to the target tissue. However, new challenges have been encountered when seeking to understand and predict the systemic disposition of liposomal formulations. The physiological barriers that limit the delivery of liposomal drugs to the targeted site are evaluated here (<xref ref-type="fig" rid="pharmaceutics-11-00110-f001">Figure 1</xref>).</p><sec id="sec3dot1-pharmaceutics-11-00110"><title>3.1. Systemic Clearance</title><p>In general, liposomes have the ability to circulate longer than small molecules via a reduction in kidney filtration. However, the in vivo persistence of conventional liposomes was not significantly prolonged as a result of rapid recognition and degradation by the MPS. Once in the bloodstream, the liposomes are quickly opsonized [<xref rid="B72-pharmaceutics-11-00110" ref-type="bibr">72</xref>] and then recognized and engulfed by the macrophages, leading to their rapid clearance [<xref rid="B73-pharmaceutics-11-00110" ref-type="bibr">73</xref>]. Specifically, the half-life of doxorubicin was only prolonged from 0.2 h to 2.5 h by Myocet<sup>&#174;</sup> [<xref rid="B74-pharmaceutics-11-00110" ref-type="bibr">74</xref>]. Liposome properties, such as surface modification, size, and zeta potential, are all determinants of opsonization [<xref rid="B72-pharmaceutics-11-00110" ref-type="bibr">72</xref>]. An effective approach to reducing opsonization and prolonging liposomal systemic persistence is to coat the liposome surface with hydrophilic polymers, i.e., PEG [<xref rid="B75-pharmaceutics-11-00110" ref-type="bibr">75</xref>]. The half-life of liposomal doxorubicin was prolonged from 2.5 h (Myocet<sup>&#174;</sup>) to 55 h (Doxil<sup>&#174;</sup>) using the pegylation technique [<xref rid="B74-pharmaceutics-11-00110" ref-type="bibr">74</xref>].</p></sec><sec id="sec3dot2-pharmaceutics-11-00110"><title>3.2. Extravasation</title><p>Functional blood vessels are essential for the delivery of the drug to the targeted tissues. Unlike the orderly organization of vessels in normal tissues, the arrangement of the tumor vessels is often disorderly, resulting in spatially and temporally heterogeneous blood perfusion [<xref rid="B76-pharmaceutics-11-00110" ref-type="bibr">76</xref>]. A positive correlation was found in vivo between tumor blood perfusion and the extent of liposome distribution using imaging-based techniques [<xref rid="B77-pharmaceutics-11-00110" ref-type="bibr">77</xref>,<xref rid="B78-pharmaceutics-11-00110" ref-type="bibr">78</xref>]. Irregular tumor vasculature is a significant barrier to the targeted delivery of liposomes to the tumor. Vascular endothelial growth factor (VEGF) inhibitors were developed to suppress angiogenesis, so as to reduce the blood supply to the tumor [<xref rid="B79-pharmaceutics-11-00110" ref-type="bibr">79</xref>]. However, mounting evidence suggests that the clinical benefit of VEGF inhibitors can largely be ascribed to normalization of the chaotic tumor vasculature, resulting in elevated blood perfusion in the tumor [<xref rid="B80-pharmaceutics-11-00110" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceutics-11-00110" ref-type="bibr">81</xref>,<xref rid="B82-pharmaceutics-11-00110" ref-type="bibr">82</xref>]. Thus, VEGF inhibitors are often exploited to improve tumor blood supply and liposome delivery.</p><p>Enhanced blood perfusion increases liposome delivery to the tumor, but does not necessarily equate to the increased exposure of the drug to the targeted cells. To reach the action sites, the liposomes need to extravasate first before reaching the targeted cells. The continuous layers of endothelial cells and the surrounding perivascular cells in the normal tissues constitute a physical barrier to the extravasation of the nanoscale liposomes, resulting in their limited distribution in normal tissue. Tumors with a highly abnormal vasculature (e.g., widened inter-endothelial cell gaps, tenuous pericyte cell contacts, and abundant fenestrated capillaries) have higher vessel permeability, thus allowing the passive diffusion of liposomes across the tumor vasculature [<xref rid="B83-pharmaceutics-11-00110" ref-type="bibr">83</xref>,<xref rid="B84-pharmaceutics-11-00110" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceutics-11-00110" ref-type="bibr">85</xref>]. The blood supply, vasculature permeability, particle size, and liposomal surface charge all affect the extravasation of liposomes. Strategies to either reduce the particle size or modify the blood vessels have the potential to enhance the extravasation of liposomes [<xref rid="B86-pharmaceutics-11-00110" ref-type="bibr">86</xref>]. Over the past three decades, several pharmacological and physical approaches have been developed to ensure blood vessel modification, such as vessel permeabilization, vessel disruption, hyperthermia, and sonoporation [<xref rid="B87-pharmaceutics-11-00110" ref-type="bibr">87</xref>].</p></sec><sec id="sec3dot3-pharmaceutics-11-00110"><title>3.3. Spatial Penetration in the Tumor Tissues</title><p>Physical disruption to the microvascular membrane and collapsed lymphatics leads to the accumulation of plasma proteins in a solid tumor, resulting in interstitial hypertension [<xref rid="B88-pharmaceutics-11-00110" ref-type="bibr">88</xref>]. Convection is diminished in tumors with elevated interstitial fluid pressure (IFP), and the penetration of liposomes is largely limited to diffusion [<xref rid="B89-pharmaceutics-11-00110" ref-type="bibr">89</xref>]. In addition, the dense extracellular matrix has been observed to drastically lower the diffusion coefficient of liposomes in tumors [<xref rid="B90-pharmaceutics-11-00110" ref-type="bibr">90</xref>,<xref rid="B91-pharmaceutics-11-00110" ref-type="bibr">91</xref>]. Thus, liposomes in tumors are characterized by a concentration gradient that extends from the perivascular area to the distal tumor cells [<xref rid="B76-pharmaceutics-11-00110" ref-type="bibr">76</xref>,<xref rid="B92-pharmaceutics-11-00110" ref-type="bibr">92</xref>]. The exposure of drugs to the distal tumor cells is often observed to be several orders of magnitude lower than that in perivascular area [<xref rid="B89-pharmaceutics-11-00110" ref-type="bibr">89</xref>]. It is believed that insufficient drug exposure compromises therapeutic efficacy. Thus, increasing tumor spatial penetration has emerged as a potentially invaluable approach with which to improve the anti-tumor efficacy of liposomes [<xref rid="B89-pharmaceutics-11-00110" ref-type="bibr">89</xref>]. For instance, VEGF receptor 2 blockade assists with vascular normalization and has been observed to increase drug penetration by reducing IFP [<xref rid="B93-pharmaceutics-11-00110" ref-type="bibr">93</xref>]. Ensuring the degradation of the extracellular matrix is another strategy that can be used to increase tumor penetration [<xref rid="B94-pharmaceutics-11-00110" ref-type="bibr">94</xref>]. Tumor spatial penetration can also be improved by modifying the liposomal properties, i.e., size and surface characteristics [<xref rid="B95-pharmaceutics-11-00110" ref-type="bibr">95</xref>].</p></sec><sec id="sec3dot4-pharmaceutics-11-00110"><title>3.4. Intracellular Uptake</title><p>Delivery of the payloads into the targeted cells is needed to ensure efficacy as most pharmacological targets of the payloads reside intracellularly, particularly for macromolecular agents (e.g., DNA and siRNA). However, a fraction of the liposomes in the interstitial space is degraded before being taken up by the tumor cells due to the acidic environment in the interstitial fluid and rapid phagocytosis by the tumor-associated macrophages. An unstable payload, i.e., a macromolecular agent, is rapidly degraded in the interstitial fluid. This compromises the therapeutic effects. Liposomes enter the tumor cells via various endocytic pathways [<xref rid="B96-pharmaceutics-11-00110" ref-type="bibr">96</xref>]. Thus, coating them with a targeting antibody can escalate tumor cell uptake [<xref rid="B97-pharmaceutics-11-00110" ref-type="bibr">97</xref>]. Once the liposomes in the endosome have been taken up by the tumor cells via endocytosis, the liposomes are either recycled to the cell surface or degraded by the acidic conditions or the residing enzymes after the endosome has matured into a late endosome and fused with the lysosome [<xref rid="B98-pharmaceutics-11-00110" ref-type="bibr">98</xref>,<xref rid="B99-pharmaceutics-11-00110" ref-type="bibr">99</xref>]. The released payload that escapes from the endosomes binds to the intracellular target to elicit the therapeutic effect. Degradation in the interstitial space and during the endocytosis process acts as a barrier and reduces the amount of payload that reaches the intracellular target.</p></sec></sec><sec id="sec4-pharmaceutics-11-00110"><title>4. Challenges to Liposomal Drug Development and a Regulatory Review</title><p>The disposition of the payload (i.e., liposomal drugs) is jointly determined by the kinetics of both the carrier and the payload itself. Compared to conventional formulations, the liposomes interact with multiple components of the physiological system, thereby making it difficult to predict the disposition behaviors of liposomal drugs. The challenges to the development and regulation of liposomal drugs are described in this section.</p><sec id="sec4dot1-pharmaceutics-11-00110"><title>4.1. The Identification of Critical Quantity Attributes</title><p>Multiple physicochemical properties (e.g., particle size, zeta potential, lipid phase transition temperature, lipid composition, and drug release kinetics) affect the multiscale mechanisms of liposomal disposition, i.e., systemic clearance, tissue extravasation, tissue penetration, and cellular internalization [<xref rid="B100-pharmaceutics-11-00110" ref-type="bibr">100</xref>]. The relationship between the physicochemical properties of liposomes and their systemic administration has been extensively investigated, and key guiding principles have been established. Nevertheless, an accurate prediction of liposomal disposition by the physicochemical properties remains impossible. For instance, pegylation reduces opsonization and interactions with the MPS [<xref rid="B101-pharmaceutics-11-00110" ref-type="bibr">101</xref>], but also hinders effective extravasation and interstitial diffusion. The desirable properties of liposomes include prolonged retention, enhanced extravasation, and effective interstitial diffusion. However, these disposition processes sometimes compromise one another, meaning that liposome-based designs must consider the integral influence of physicochemical properties on the dispositional processes.</p></sec><sec id="sec4dot2-pharmaceutics-11-00110"><title>4.2. The Gap in Translation from Animal Models to the Clinic</title><p>The currently approved liposomes have achieved only a moderate improvement in patient survival compared to the conventional formulations. Therefore, it is vital to determine whether a xenograft tumor model is appropriate for an evaluation of liposomes even though subcutaneous xenogeneic tumor models remain the most popular preclinical model for liposome development. Dramatic differences have been observed between animal tumor models and clinical tumors, and this largely explains the low rate of successful conversion of preclinical efficacy to a clinical survival benefit.</p><p>The EPR effect has been broadly observed in xenograft tumor models. It serves as a fundamental principle of nanodrug delivery. However, there is significant heterogeneity in the EPR effect within and between tumor types. It has been reported that different tumor types have different vascular pore sizes and that the maximum pore size changes according to the location of a given type of tumor (i.e., primary vs. metastatic) [<xref rid="B83-pharmaceutics-11-00110" ref-type="bibr">83</xref>,<xref rid="B102-pharmaceutics-11-00110" ref-type="bibr">102</xref>]. Moreover, EPR-dependent delivery is often complicated by erratic vascular distribution, high IFP and poor blood perfusion in the tumor [<xref rid="B103-pharmaceutics-11-00110" ref-type="bibr">103</xref>]. The difference in tumor vascular permeability between the xenograft and a clinical tumor elucidates the low success rate achieved for clinical conversion [<xref rid="B104-pharmaceutics-11-00110" ref-type="bibr">104</xref>]. Using a xenograft model, it usually takes approximately 2~4 weeks for the tumor to grow to 1 cm (0.5 g) in diameter [<xref rid="B105-pharmaceutics-11-00110" ref-type="bibr">105</xref>]. In contrast, a clinical diagnosis is only possible after several years. As a result, the tumor vessels in the murine xenograft model are often poorly differentiated and tend to be more permeable than those of a clinical tumor that develops more slowly. Tumor vessel permeability has a close correlation with histologic type and the site of the tumor according to rodent studies [<xref rid="B83-pharmaceutics-11-00110" ref-type="bibr">83</xref>,<xref rid="B102-pharmaceutics-11-00110" ref-type="bibr">102</xref>]. A conventional allometric relationship in the clearance of liposomes across mice, rats, dogs, and humans, largely due to inconsistencies in vascular structure and permeability, was not identified in a recent study [<xref rid="B106-pharmaceutics-11-00110" ref-type="bibr">106</xref>].</p></sec><sec id="sec4dot3-pharmaceutics-11-00110"><title>4.3. The Quantitative Pharmacokinetic&#8211;Pharmacodynamic Relationship</title><p>Liposomes are designed to augment therapeutic efficacy and reduce toxicity, primarily by influencing the tissue distribution profiles [<xref rid="B107-pharmaceutics-11-00110" ref-type="bibr">107</xref>]. A quantitative understanding of the multiscale mechanisms of liposomal disposition and influencing factors is critical for the development and regulatory evaluation of liposomal drugs.</p><p>The therapeutic efficacy of conventional formulations is generally accurately predicted using systemic PK parameters (e.g., maximum serum/plasma concentration and area under the concentration-time curve). Unlike conventional formulations, the systemic drug exposure of liposomal drugs should not be used to predict efficacy. The only active component of liposomal drugs is the free drug, the active pharmaceutical ingredient (API) released from the liposome. However, the disposition of the API at the target site is usually jointly defined by the local disposition of the API and the drug release kinetics of locally deposited liposomes. Thus, the systemic PK parameters for either intact liposomes or the free drug are not capable of directly predicting the tissue exposure of the free drug and the efficacy and toxicity.</p><p>Unfortunately, it remains technically challenging to directly measure the concentration of free APIs in the targeted tissues. The fraction of nuclear doxorubicin to total doxorubicin in a xenograft tumor was reported to be approximately 40~50% and 25% after dosing with Doxil<sup>&#174;</sup> and dioleoylphosphatidylcholine-pegylated liposomal doxorubicin, respectively, in a study by Laginha et al. [<xref rid="B70-pharmaceutics-11-00110" ref-type="bibr">70</xref>]. Thus, an integrated PK&#8211;PD relationship with regard to the systemic and local kinetics of both the liposomes and free APIs is extremely valuable. It is challenging trying to establish a solid PK&#8211;PD relationship for liposomal drugs, but doing so is critical to their development and evaluation.</p></sec></sec><sec id="sec5-pharmaceutics-11-00110"><title>5. The Application of Pharmacokinetic&#8211;Pharmacodynamic Modeling and Simulation Systems in Liposomal Drug Delivery</title><p>The kinetics of free APIs at the target site should be used to develop the PK&#8211;PD relationship for a given liposome. PK&#8211;PD modeling and simulation has been used to bypass the challenge of measuring free APIs at the target site. The targeted exposure of free APIs can be predicted by using a PK model that integrates the multiscale dispositions of liposomal drugs, including the systemic and local kinetics of liposomes and the free drugs, as well as drug release. Subsequently, the efficacy can be predicted using a PD model based on the predicted targeted exposure of the free APIs. The developed PK&#8211;PD model could be further utilized to identify the critical quality attributes of liposomes in efficacy and to bridge the animal study and clinical study. A series of PK&#8211;PD modeling and simulation systems for application to liposomal drugs was identified in this section (<xref rid="pharmaceutics-11-00110-t002" ref-type="table">Table 2</xref>).</p><sec id="sec5dot1-pharmaceutics-11-00110"><title>5.1. Physiologically-Based Pharmacokinetic Modeling and Simulation</title><p>As previously discussed, the multiscale mechanisms of liposomal drug disposition are influenced by numerous physiological factors. Zamboni et al. reported that physiological factors (including age, body composition, monocytes, gender, and liver disease status) shape the disposition of liposomal drugs [<xref rid="B108-pharmaceutics-11-00110" ref-type="bibr">108</xref>,<xref rid="B109-pharmaceutics-11-00110" ref-type="bibr">109</xref>,<xref rid="B110-pharmaceutics-11-00110" ref-type="bibr">110</xref>]. Using a &#8220;bottom-up&#8221; approach, a general whole-body physiologically-based PK (PBPK) model (<xref ref-type="fig" rid="pharmaceutics-11-00110-f002">Figure 2</xref>A) and a mechanism-based model for tumor (<xref ref-type="fig" rid="pharmaceutics-11-00110-f002">Figure 2</xref>B) can be proposed to capture the detailed disposition of both liposomes and payload in the biological system. Such PBPK models could be used to investigate the influence of drug-associated factors and physiological factors (such as the MPS) on the multiscale mechanisms of liposomal disposition. Currently, PBPK models are widely used in small molecular drug development and regulatory reviews [<xref rid="B111-pharmaceutics-11-00110" ref-type="bibr">111</xref>,<xref rid="B112-pharmaceutics-11-00110" ref-type="bibr">112</xref>,<xref rid="B113-pharmaceutics-11-00110" ref-type="bibr">113</xref>,<xref rid="B114-pharmaceutics-11-00110" ref-type="bibr">114</xref>,<xref rid="B115-pharmaceutics-11-00110" ref-type="bibr">115</xref>,<xref rid="B116-pharmaceutics-11-00110" ref-type="bibr">116</xref>]. PBPK modeling and simulation has recently emerged as a powerful tool for delineating the PK and tissue distribution profiles of liposomal drugs [<xref rid="B17-pharmaceutics-11-00110" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-11-00110" ref-type="bibr">18</xref>,<xref rid="B117-pharmaceutics-11-00110" ref-type="bibr">117</xref>].</p><sec id="sec5dot1dot1-pharmaceutics-11-00110"><title>5.1.1. Simplified PBPK Model</title><p>Harashima et al. developed a hybrid model to correlate the systemic disposition of liposomes with the targeted exposure of the free API [<xref rid="B118-pharmaceutics-11-00110" ref-type="bibr">118</xref>,<xref rid="B119-pharmaceutics-11-00110" ref-type="bibr">119</xref>]. A compartmental model was used to describe the systemic PK profiles of encapsulated and released doxorubicin. The tumor, which is the target tissue, was listed as an individual compartment to describe the disposition of encapsulated and released doxorubicin in tumors. The tumor compartment contains capillary, interstitial, and tumor cell sub-compartments and is linked to the systemic compartment by blood flow to the tumor via the capillary sub-compartments. Using this hybrid model, the systemic PK profiles of the liposomes were assessed to predict the tumor distribution profile of free doxorubicin in an attempt to establish the PK&#8211;PD relationship. The developed PK&#8211;PD framework was then used to assess the influence of the physicochemical and physiological properties of the liposomes on the exposure of the tumor to free doxorubicin and the anti-tumor effect [<xref rid="B118-pharmaceutics-11-00110" ref-type="bibr">118</xref>]. Liposomal retention in tumors and the local release rate were observed to have a pivotal influence on the anti-tumor effect of liposomal drugs.</p><p>The impact of physiological variations on liposomal disposition properties can also be evaluated using PBPK models. Hendriks et al. developed a hybrid PBPK model and assessed the impact of tumor physiology on the cellular and subcellular transport of doxorubicin inside tumors [<xref rid="B120-pharmaceutics-11-00110" ref-type="bibr">120</xref>]. This work was an example of the use of PBPK modeling and simulation to identify critical physiological factors to improve treatment outcomes and facilitate trans-species or population translation.</p><p>Apgar et al. developed a systems model to quantify liposomal RNA disposition and its effect on serum bilirubin [<xref rid="B121-pharmaceutics-11-00110" ref-type="bibr">121</xref>]. The delivery of RNA to the hepatocytes was quantified by a simplified PBPK model of the kinetics of liposomal RNA degradation, biodistribution, attachment to hepatocytes, endocytic uptake, and intracellular degradation processes in the liver. The effect of the delivered RNA on the regulation of glucuronidation and bilirubin clearance was systematically investigated. Lastly, this PBPK model was applied to bridge preclinical and clinical studies and predict the first human dose.</p></sec><sec id="sec5dot1dot2-pharmaceutics-11-00110"><title>5.1.2. Whole-Body PBPK Model</title><p>Key factors and processes can be integrated using a PBPK model to assess the PK&#8211;PD relationship. Kagan et al. developed a dual-layer, whole-body PBPK model to evaluate and describe the disposition of intact liposomes and free amphotericin B (Ambisome<sup>&#174;</sup>) [<xref rid="B122-pharmaceutics-11-00110" ref-type="bibr">122</xref>]. Drug release kinetics were used to connect the two PBPK layers. Model parameters were optimized to correlate the plasma and tissue concentrations with the time profiles. This was the first whole-body PBPK model to be developed and was capable of simultaneously quantifying the tissue disposition profiles of the encapsulated and free drugs.</p></sec></sec><sec id="sec5dot2-pharmaceutics-11-00110"><title>5.2. PK&#8211;PD Modeling System with Spatiotemporal Characterization</title><p>The hyperpermeability of blood vessels in a tumor and dysfunction of the lymphatic system enable the accumulation of liposomal drugs in the tumor. This EPR concept is the fundamental principle that is applied to liposomes with respect to the targeted delivery of cytotoxic drugs to solid tumors. The spatial biodistribution of liposomes in tumors is highly heterogeneous [<xref rid="B92-pharmaceutics-11-00110" ref-type="bibr">92</xref>]. Liposomes in the tumor tissues are mainly located in the perivascular areas and roots of the capillary sprouts, far from the tumor cells. Heterogeneous tumor distribution is believed to explain the moderate improvement in patient survival due to approved liposomal drugs [<xref rid="B123-pharmaceutics-11-00110" ref-type="bibr">123</xref>]. The heterogeneous distribution of liposomes in tumors is associated with irregular blood vessels in the tumors, elevated IFP, and dense extracellular matrix cell packing. These properties limit the extravasation and penetration of the liposomes. Several system-based models have been proposed to analyze the impact of tumor vasculature and physical properties on heterogeneity in spatial distribution [<xref rid="B95-pharmaceutics-11-00110" ref-type="bibr">95</xref>,<xref rid="B124-pharmaceutics-11-00110" ref-type="bibr">124</xref>,<xref rid="B125-pharmaceutics-11-00110" ref-type="bibr">125</xref>,<xref rid="B126-pharmaceutics-11-00110" ref-type="bibr">126</xref>].</p><p>Macklin et al. developed a mathematical model to describe solid tumor growth and tumor-induced angiogenesis [<xref rid="B127-pharmaceutics-11-00110" ref-type="bibr">127</xref>]. Based on this model, Frieboes et al. simulated tumor growth and the evolution of the tumor microenvironment over time. They analyzed the influence of the tumor microenvironment properties, particle size, ligand density, and ligand-receptor binding affinity on the spatiotemporal distribution of nanoparticles in tumors [<xref rid="B125-pharmaceutics-11-00110" ref-type="bibr">125</xref>]. Furthermore, the effects of drug-loading methods, release rates, and diffusivity on treatment efficacy were also assessed [<xref rid="B128-pharmaceutics-11-00110" ref-type="bibr">128</xref>]. The findings of these studies elucidate the relationship between physiological and physicochemical properties or liposomal disposition and antitumor efficacy.</p><p>The impaired blood vessels in tumors expedite the extravasation of nanocarriers into the tumor. However, the increased permeability of the fluid elevates IFP in the tumor, hindering the extravasation of nanoparticles. Thus, normalization of the vasculature can be used to improve extravasation by reducing IFP in the tumor. Jain et al. developed a mathematical model to evaluate the effect of vascular normalization on the delivery of nanomedicines to tumors [<xref rid="B95-pharmaceutics-11-00110" ref-type="bibr">95</xref>]. A two-dimensional percolation network was constructed with an inlet and an outlet to mimic the tumor microvasculature structure. Blood flow, transvascular fluid flow, interstitial fluid transport, drug transport, and tumor vessel wall permeability were all considered. Vascular normalization improved delivery of the smaller nanoparticles to the tumor, but hindered transport of the larger ones [<xref rid="B95-pharmaceutics-11-00110" ref-type="bibr">95</xref>]. After electrostatic interactions between the particles and the pores in the vessel wall were taken into account, this model was applied to evaluate the effect of the particle surface charge on the distribution of nanoparticles in the tumor [<xref rid="B129-pharmaceutics-11-00110" ref-type="bibr">129</xref>]. To further guide particle engineering, this model was also used to investigate the impact of particle size, drug release rate, and targeted binding affinity on intratumor distribution [<xref rid="B130-pharmaceutics-11-00110" ref-type="bibr">130</xref>,<xref rid="B131-pharmaceutics-11-00110" ref-type="bibr">131</xref>]. According to their analyses, small particles (&#8804;10 nm) are more effective in tumor distribution and deep penetration. To prevent the fast clearance of small particles and their extravasation to normal tissues, a two-stage approach was proposed to encapsulate the 5-nm secondary particles into a 20-nm primary particle. The release rate is positively related to the antitumor efficacy of nanoparticles, so a relatively high value of release rate is preferable for liposomes. To improve the efficacy, an appropriate targeted binding affinity is required as a relatively high binding rate can trap the drug. The simulation suggested that a binding rate constant of around 1000 (M<sup>&#8722;1</sup>s<sup>&#8722;1</sup>) was the optimal rate for killing tumor cells.</p></sec><sec id="sec5dot3-pharmaceutics-11-00110"><title>5.3. Combination of In Vitro Study and the PK&#8211;PD Modeling System</title><p>The systemic disposition profile of liposomal drugs depends on the physicochemical properties of liposomes and the biological system. For instance, the extravasation rate of liposomes is determined not only by the particle size, surface charges, and shapes, but also by the vascular endothelial structures and the permeability of the targeted tissue. Kirtane et al. developed a system-based model to predict the targeted exposure of nanoparticles based on particle and vascular pore sizes [<xref rid="B132-pharmaceutics-11-00110" ref-type="bibr">132</xref>]. They concluded that a particle size that was universally optimal for all types of tumors could not be identified. Optimal particle properties were found to be contingent on the type and features of the tumor. The high variability of experimental animals often confounds the identification of influencial particle parameters on each process of particle disposition. An in vitro assay under well-controlled biological conditions is a more desirable tool than the in vivo study for identifying the effect of particle properties on particle disposition. However, how to translate the in vitro assay result to in vivo liposome disposition prosperities remains a major obstacle. In vitro&#8212;in vivo correlation (IVIVC) is defined by the FDA as &#8220;a predictive mathematical model that is used to describe the relationship between the in vitro property of a dosage form and a relevant in vivo response&#8221; [<xref rid="B133-pharmaceutics-11-00110" ref-type="bibr">133</xref>]. Once IVIVC has been established and validated, the results of in vitro studies can be used to predict drug performance in vivo. The use of a combination of well-controlled high-throughput in vitro assays and IVIVC approaches between particle properties and the in vivo disposition (e.g., clearance, extravasation) of the liposomes holds promise in liposome optimization. Moreover, PK&#8211;PD modeling system could integrate IVIVC to predict the targeted exposure of API and then the efficacy of the liposome based on the in vitro measurable particle properties.</p><p>Recently, Mayer et. al. developed an IVIVC approach to predict liposome in vivo release [<xref rid="B134-pharmaceutics-11-00110" ref-type="bibr">134</xref>]. Multilamellar vesicles were used as &#8220;acceptors&#8221; to mimic the in vivo membrane and predict drug release in vivo. This in vitro release testing method accurately predicted the in vivo release characteristics of liposomal drugs compared to the commonly used dialysis membrane method. The lipid membrane pool in the circulation and tissues helps to explain the poor correlation between in vitro and in vivo drug release.</p><p>In a similar study, a two-stage reverse dialysis method (i.e., dialysis in pH 7.4 HEPES buffer solution [stage 1] and dialysis in 1% TX100 solution in HEPES buffer solution [stage 2]) was developed to mimic the release of the drug into the blood and targeted tissue [<xref rid="B135-pharmaceutics-11-00110" ref-type="bibr">135</xref>]. Premature drug release can also be induced by plasma protein adsorption and the subsequent identification of liposomes by the MPS. In an attempt to predict systemic clearance, Crielaard et al. characterized liposome&#8211;protein interactions and liposome aggregations using surface plasmon resonance and single-molecule tracking fluorescence microscopy [<xref rid="B136-pharmaceutics-11-00110" ref-type="bibr">136</xref>]. Aggregation was not observed, and clearance of the liposomes was seen to positively relate to interactions between the liposomes and proteins, suggesting that liposome&#8211;protein interactions can be used to predict the systemic clearance of liposomes.</p><p>The developed IVIVC could be incorporated into a PBPK model to quantify the effect of liposomal properties on the multiscale mechanisms of liposomal disposition. Based on a meta-analysis of data in the literature, an IVIVC was developed in our unpublished study between liposomal particle size, surface charge, and pegylation and systemic clearance and tumor disposition [<xref rid="B137-pharmaceutics-11-00110" ref-type="bibr">137</xref>]. These relationships were then incorporated into a PBPK model of liposomal doxorubicin to identify the most sensitive liposomal property characteristics in relation to high efficacy and low toxicity. Importantly, this integrated modeling framework has the capacity to identify critical or trivial physicochemical properties, which would potentially benefit the regulatory reviews that are conducted to evaluate generic liposomal drugs.</p></sec></sec><sec id="sec6-pharmaceutics-11-00110"><title>6. Perspective and Future Direction</title><p>Liposomal formulations have been developed to improve the therapeutic index of encapsulated drugs by altering the balance of on- and off-target distribution. The use of PK&#8211;PD modeling and simulation systems is considered a powerful means of identifying system- and drug-associated factors that influence the multiscale mechanisms of liposomal disposition. Several challenges need to be addressed in order to further improve PK&#8211;PD models to enhance the development and regulation of liposomal drugs.</p><p>Firstly, it is important to note that the therapeutic effects of liposomal drugs are elicited by the free payload at the site of action. However, reliable quantification-based approaches to measure free payloads in low abundance at the targeted sites are still lacking, particularly in clinical situations. Although PK&#8211;PD modeling and simulation systems are able to predict the targeted exposure of free payloads, experimental measurement of the free drug exposure at the targeted sites is required for additional model verification.</p><p>Secondly, the key advantages of PK&#8211;PD modeling and simulation include the ability to integrate the multiscale disposition mechanisms of liposomal disposition and elucidate the quantitative relationships between the physicochemical properties of liposomes and the systemic and target disposition behavior (IVIVC). Unfortunately, only the IVIVC between drug release and liposome clearance has been established. IVIVCs between other liposomal properties and other liposome disposition processes (e.g., penetration, extravasation, and endocytosis) have not been reported in literature. Moreover, the available IVIVC is highly formulation- or animal model-dependent and needs to be verified before scaling to other scenarios.</p><p>Thirdly, the developed PK&#8211;PD modeling and simulation systems or PBPK models take into account many physiological factors, but many of these are highly variable across populations and some of them are even influenced by the treatment of liposomal drugs. This creates additional sources of variability in model prediction and simulation. When using PK&#8211;PD modeling and simulation models for clinical translation, it is important to consider variations in the sociodemographic characteristics of the patients and to evaluate whether it would result in clinically meaningful changes in response to liposomal drug treatment.</p><p>In conclusion, PK&#8211;PD modeling and simulation systems provide an integrated and upgradable approach to guide the development and regulation of liposomal drugs. The present review summarized the physiological factors that affect the targeted delivery of liposomal drugs, challenges that influence the development and regulation of liposomal drugs, and the application of PK&#8211;PD modeling and simulation systems to address these challenges.</p></sec></body><back><ack><title>Acknowledgments</title><p>We appreciate the insightful discussions with our collaborators on this topic. </p></ack><notes><title>Funding</title><p>This work was supported by grants from NIH (R35 GM119661), the 111 incubation project (BC2018024) and the Natural Science Foundation of China (No. 81503145).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-11-00110"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bangham</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Horne</surname><given-names>R.W.</given-names></name></person-group><article-title>Negatie staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope</article-title><source>J. Mol. Biol.</source><year>1964</year><volume>8</volume><fpage>660</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(64)80115-7</pub-id><pub-id pub-id-type="pmid">14187392</pub-id></element-citation></ref><ref id="B2-pharmaceutics-11-00110"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bangham</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Standish</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>J.C.</given-names></name></person-group><article-title>Diffusion of univalent ions across the lamellae of swollen phospholipids</article-title><source>J. Mol. Biol.</source><year>1965</year><volume>13</volume><fpage>238</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(65)80093-6</pub-id><pub-id pub-id-type="pmid">5859039</pub-id></element-citation></ref><ref id="B3-pharmaceutics-11-00110"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregoriadis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ryman</surname><given-names>B.E.</given-names></name></person-group><article-title>Liposomes as carriers of enzymes or drugs: A new approach to the treatment of storage diseases</article-title><source>Biochem. J.</source><year>1971</year><volume>124</volume><fpage>58p</fpage><pub-id pub-id-type="doi">10.1042/bj1240058P</pub-id><pub-id pub-id-type="pmid">5130994</pub-id><pub-id pub-id-type="pmcid">PMC1177319</pub-id></element-citation></ref><ref id="B4-pharmaceutics-11-00110"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregoriadis</surname><given-names>G.</given-names></name></person-group><article-title>Drug entrapment in liposomes</article-title><source>FEBS Lett.</source><year>1973</year><volume>36</volume><fpage>292</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(73)80394-1</pub-id><pub-id pub-id-type="pmid">4763309</pub-id></element-citation></ref><ref id="B5-pharmaceutics-11-00110"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregoriadis</surname><given-names>G.</given-names></name></person-group><article-title>The carrier potential of liposomes in biology and medicine (second of two parts)</article-title><source>N. Engl. J. Med.</source><year>1976</year><volume>295</volume><fpage>765</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1056/NEJM197609302951406</pub-id><pub-id pub-id-type="pmid">785256</pub-id></element-citation></ref><ref id="B6-pharmaceutics-11-00110"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gregoriadis</surname><given-names>G.</given-names></name></person-group><article-title>The carrier potential of liposomes in biology and medicine (first of two parts)</article-title><source>N. Engl. J. Med.</source><year>1976</year><volume>295</volume><fpage>704</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1056/NEJM197609232951305</pub-id><pub-id pub-id-type="pmid">958245</pub-id></element-citation></ref><ref id="B7-pharmaceutics-11-00110"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsukagoshi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sakurai</surname><given-names>Y.</given-names></name></person-group><article-title>Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210</article-title><source>Gann</source><year>1975</year><volume>66</volume><fpage>719</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">1225724</pub-id></element-citation></ref><ref id="B8-pharmaceutics-11-00110"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Steck</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>W.L.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Waits</surname><given-names>V.B.</given-names></name><name name-style="western"><surname>Hendricks</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>G.M.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Hanson</surname><given-names>W.L.</given-names></name></person-group><article-title>Therapy of leishmaniasis: Superior efficacies of liposome-encapsulated drugs</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1978</year><volume>75</volume><fpage>2959</fpage><lpage>2963</lpage><pub-id pub-id-type="doi">10.1073/pnas.75.6.2959</pub-id><pub-id pub-id-type="pmid">208079</pub-id><pub-id pub-id-type="pmcid">PMC392686</pub-id></element-citation></ref><ref id="B9-pharmaceutics-11-00110"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Berestein</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fainstein</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hopfer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Keating</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosenblum</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Luna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hersh</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study</article-title><source>J. Infect. Dis.</source><year>1985</year><volume>151</volume><fpage>704</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1093/infdis/151.4.704</pub-id><pub-id pub-id-type="pmid">3973417</pub-id></element-citation></ref><ref id="B10-pharmaceutics-11-00110"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabizon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goren</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fuks</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Barenholz</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dagan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meshorer</surname><given-names>A.</given-names></name></person-group><article-title>Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers</article-title><source>Cancer Res.</source><year>1983</year><volume>43</volume><fpage>4730</fpage><lpage>4735</lpage><pub-id pub-id-type="pmid">6883331</pub-id></element-citation></ref><ref id="B11-pharmaceutics-11-00110"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>H.</given-names></name></person-group><article-title>Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity</article-title><source>Adv. Drug Deliv. Rev.</source><year>2015</year><volume>91</volume><fpage>3</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.01.002</pub-id><pub-id pub-id-type="pmid">25579058</pub-id></element-citation></ref><ref id="B12-pharmaceutics-11-00110"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>H.</given-names></name></person-group><article-title>A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs</article-title><source>Cancer Res.</source><year>1986</year><volume>46</volume><fpage>6387</fpage><lpage>6392</lpage><pub-id pub-id-type="pmid">2946403</pub-id></element-citation></ref><ref id="B13-pharmaceutics-11-00110"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barenholz</surname><given-names>Y.</given-names></name></person-group><article-title>Doxil(R)--the first FDA-approved nano-drug: Lessons learned</article-title><source>J. Control. Release</source><year>2012</year><volume>160</volume><fpage>117</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.03.020</pub-id><pub-id pub-id-type="pmid">22484195</pub-id></element-citation></ref><ref id="B14-pharmaceutics-11-00110"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bulbake</surname><given-names>U.</given-names></name><name name-style="western"><surname>Doppalapudi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kommineni</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>W.</given-names></name></person-group><article-title>Liposomal Formulations in Clinical Use: An Updated Review</article-title><source>Pharmaceutics</source><year>2017</year><volume>9</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics9020012</pub-id><pub-id pub-id-type="pmid">28346375</pub-id><pub-id pub-id-type="pmcid">PMC5489929</pub-id></element-citation></ref><ref id="B15-pharmaceutics-11-00110"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucas</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Madden</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Zamboni</surname><given-names>W.C.</given-names></name></person-group><article-title>Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents</article-title><source>Expert Opin. Drug Metab. Toxicol.</source><year>2015</year><volume>11</volume><fpage>1419</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1517/17425255.2015.1057496</pub-id><pub-id pub-id-type="pmid">26173794</pub-id></element-citation></ref><ref id="B16-pharmaceutics-11-00110"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garralda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dienstmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tabernero</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology</article-title><source>Am. Soc. Clin. Oncol. Educ. Book</source><year>2017</year><volume>37</volume><fpage>210</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.14694/EDBK_180460</pub-id><pub-id pub-id-type="pmid">28561730</pub-id></element-citation></ref><ref id="B17-pharmaceutics-11-00110"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tyner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name></person-group><article-title>Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles</article-title><source>AAPS J.</source><year>2017</year><volume>19</volume><fpage>26</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1208/s12248-016-0010-3</pub-id><pub-id pub-id-type="pmid">27834047</pub-id></element-citation></ref><ref id="B18-pharmaceutics-11-00110"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>D.</given-names></name><name name-style="western"><surname>He</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name></person-group><article-title>Physiologically Based Pharmacokinetic Modeling of Nanoparticles</article-title><source>J. Pharm. Sci.</source><year>2019</year><volume>108</volume><fpage>58</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2018.10.037</pub-id><pub-id pub-id-type="pmid">30385282</pub-id><pub-id pub-id-type="pmcid">PMC6311421</pub-id></element-citation></ref><ref id="B19-pharmaceutics-11-00110"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>R.B.</given-names></name></person-group><article-title>The anthracyclines: will we ever find a better doxorubicin?</article-title><source>Semin. Oncol.</source><year>1992</year><volume>19</volume><fpage>670</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">1462166</pub-id></element-citation></ref><ref id="B20-pharmaceutics-11-00110"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Honbo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Karliner</surname><given-names>J.S.</given-names></name></person-group><article-title>Doxorubicin cardiomyopathy</article-title><source>Cardiology</source><year>2010</year><volume>115</volume><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1159/000265166</pub-id><pub-id pub-id-type="pmid">20016174</pub-id><pub-id pub-id-type="pmcid">PMC2848530</pub-id></element-citation></ref><ref id="B21-pharmaceutics-11-00110"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Octavia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tocchetti</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Gabrielson</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>S.</given-names></name><name name-style="western"><surname>Crijns</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Moens</surname><given-names>A.L.</given-names></name></person-group><article-title>Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies</article-title><source>J. Mol. Cell. Cardiol.</source><year>2012</year><volume>52</volume><fpage>1213</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2012.03.006</pub-id><pub-id pub-id-type="pmid">22465037</pub-id></element-citation></ref><ref id="B22-pharmaceutics-11-00110"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>F.J.</given-names></name></person-group><article-title>Advantages of liposomal delivery systems for anthracyclines</article-title><source>Semin. Oncol.</source><year>2004</year><volume>31</volume><fpage>5</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2004.08.001</pub-id><pub-id pub-id-type="pmid">15717735</pub-id></element-citation></ref><ref id="B23-pharmaceutics-11-00110"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabizon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Catane</surname><given-names>R.</given-names></name><name name-style="western"><surname>Uziely</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Safra</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barenholz</surname><given-names>Y.</given-names></name></person-group><article-title>Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes</article-title><source>Cancer Res.</source><year>1994</year><volume>54</volume><fpage>987</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">8313389</pub-id></element-citation></ref><ref id="B24-pharmaceutics-11-00110"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mross</surname><given-names>K.</given-names></name><name name-style="western"><surname>Niemann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Massing</surname><given-names>U.</given-names></name><name name-style="western"><surname>Drevs</surname><given-names>J.</given-names></name><name name-style="western"><surname>Unger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bhamra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Swenson</surname><given-names>C.E.</given-names></name></person-group><article-title>Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study</article-title><source>Cancer Chemother. Pharmacol.</source><year>2004</year><volume>54</volume><fpage>514</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1007/s00280-004-0825-y</pub-id><pub-id pub-id-type="pmid">15322827</pub-id></element-citation></ref><ref id="B25-pharmaceutics-11-00110"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batist</surname><given-names>G.</given-names></name></person-group><article-title>Cardiac safety of liposomal anthracyclines</article-title><source>Cardiovasc. Toxicol.</source><year>2007</year><volume>7</volume><fpage>72</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/s12012-007-0014-4</pub-id><pub-id pub-id-type="pmid">17652807</pub-id></element-citation></ref><ref id="B26-pharmaceutics-11-00110"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batist</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ramakrishnan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Chandrasekharan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gutheil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guthrie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khojasteh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Hoelzer</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer</article-title><source>J. Clin. Oncol.</source><year>2001</year><volume>19</volume><fpage>1444</fpage><lpage>1454</lpage><pub-id pub-id-type="doi">10.1200/JCO.2001.19.5.1444</pub-id><pub-id pub-id-type="pmid">11230490</pub-id></element-citation></ref><ref id="B27-pharmaceutics-11-00110"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Wigler</surname><given-names>N.</given-names></name><name name-style="western"><surname>Inbar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosso</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grischke</surname><given-names>E.</given-names></name><name name-style="western"><surname>Santoro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Catane</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kieback</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Tomczak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ackland</surname><given-names>S.P.</given-names></name><etal/></person-group><article-title>Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer</article-title><source>Ann. Oncol.</source><year>2004</year><volume>15</volume><fpage>440</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">14998846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdh097</pub-id></element-citation></ref><ref id="B28-pharmaceutics-11-00110"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhowmik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhowmick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maiti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chakra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shahi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rajamannar</surname><given-names>T.</given-names></name></person-group><article-title>Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil((R)) or Caelyx((R)) in advanced ovarian cancer</article-title><source>Cancer Chemother. Pharmacol.</source><year>2018</year><pub-id pub-id-type="doi">10.1007/s00280-018-3643-3</pub-id><pub-id pub-id-type="pmid">29995186</pub-id></element-citation></ref><ref id="B29-pharmaceutics-11-00110"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mamidi</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stellar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tonelli</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Angiuoli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fung</surname><given-names>M.C.</given-names></name></person-group><article-title>Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?</article-title><source>Cancer Chemother. Pharmacol.</source><year>2010</year><volume>66</volume><fpage>1173</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1007/s00280-010-1406-x</pub-id><pub-id pub-id-type="pmid">20661737</pub-id></element-citation></ref><ref id="B30-pharmaceutics-11-00110"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>L.</given-names></name><name name-style="western"><surname>Burney</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nyshadham</surname><given-names>P.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>R.L.</given-names></name></person-group><article-title>Equivalency challenge: Evaluation of Lipodox(R) as the generic equivalent for Doxil(R) in a human ovarian cancer orthotropic mouse model</article-title><source>Gynecol. Oncol.</source><year>2016</year><volume>141</volume><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2016.02.033</pub-id><pub-id pub-id-type="pmid">26946092</pub-id></element-citation></ref><ref id="B31-pharmaceutics-11-00110"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burade</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bhowmick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maiti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zalawadia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thennati</surname><given-names>R.</given-names></name></person-group><article-title>Lipodox(R) (generic doxorubicin hydrochloride liposome injection): In vivo efficacy and bioequivalence versus Caelyx(R) (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><elocation-id>405</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-017-3377-3</pub-id><pub-id pub-id-type="pmid">28587612</pub-id><pub-id pub-id-type="pmcid">PMC5461687</pub-id></element-citation></ref><ref id="B32-pharmaceutics-11-00110"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burade</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bhowmick</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maiti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zalawadia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rajamannar</surname><given-names>T.</given-names></name></person-group><article-title>Comparative plasma and tissue distribution of Sun Pharma&#8217;s generic doxorubicin HCl liposome injection versus Caelyx((R)) (doxorubicin HCl liposome injection) in syngeneic fibrosarcoma-bearing BALB/c mice and Sprague-Dawley rats</article-title><source>Cancer Chemother. Pharmacol.</source><year>2017</year><volume>79</volume><fpage>899</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1007/s00280-017-3278-9</pub-id><pub-id pub-id-type="pmid">28349166</pub-id><pub-id pub-id-type="pmcid">PMC5403873</pub-id></element-citation></ref><ref id="B33-pharmaceutics-11-00110"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petre</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Dittmer</surname><given-names>D.P.</given-names></name></person-group><article-title>Liposomal daunorubicin as treatment for Kaposi&#8217;s sarcoma</article-title><source>Int. J. Nanomed.</source><year>2007</year><volume>2</volume><fpage>277</fpage><lpage>288</lpage><pub-id pub-id-type="pmcid">PMC2676651</pub-id><pub-id pub-id-type="pmid">18019828</pub-id></element-citation></ref><ref id="B34-pharmaceutics-11-00110"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forssen</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Coulter</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Proffitt</surname><given-names>R.T.</given-names></name></person-group><article-title>Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors</article-title><source>Cancer Res.</source><year>1992</year><volume>52</volume><fpage>3255</fpage><lpage>3261</lpage><pub-id pub-id-type="pmid">1596882</pub-id></element-citation></ref><ref id="B35-pharmaceutics-11-00110"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Espina</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Muggia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cabriales</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tulpule</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esplin</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Liebman</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Forssen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>A.M.</given-names></name></person-group><article-title>Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin</article-title><source>J. Clin. Oncol.</source><year>1995</year><volume>13</volume><fpage>996</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1200/JCO.1995.13.4.996</pub-id><pub-id pub-id-type="pmid">7707129</pub-id></element-citation></ref><ref id="B36-pharmaceutics-11-00110"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fumagalli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zucchetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Parisi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vigano</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Zecca</surname><given-names>B.</given-names></name><name name-style="western"><surname>Careddu</surname><given-names>A.</given-names></name><name name-style="western"><surname>D&#8217;Incalci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lazzarin</surname><given-names>A.</given-names></name></person-group><article-title>The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi&#8217;s sarcoma</article-title><source>Cancer Chemother. Pharmacol.</source><year>2000</year><volume>45</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1007/s002800051025</pub-id><pub-id pub-id-type="pmid">10854138</pub-id></element-citation></ref><ref id="B37-pharmaceutics-11-00110"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Fathi</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>A.M.</given-names></name></person-group><article-title>Reformulating acute myeloid leukemia: Liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML</article-title><source>Onco. Targets Ther.</source><year>2018</year><volume>11</volume><fpage>3425</fpage><lpage>3434</lpage><pub-id pub-id-type="doi">10.2147/OTT.S141212</pub-id><pub-id pub-id-type="pmid">29928134</pub-id><pub-id pub-id-type="pmcid">PMC6003284</pub-id></element-citation></ref><ref id="B38-pharmaceutics-11-00110"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tardi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Johnstone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harasym</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harasym</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zisman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Harvie</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bermudes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>L.</given-names></name></person-group><article-title>In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy</article-title><source>Leuk. Res.</source><year>2009</year><volume>33</volume><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2008.06.028</pub-id><pub-id pub-id-type="pmid">18676016</pub-id></element-citation></ref><ref id="B39-pharmaceutics-11-00110"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krauss</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Manning</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Janoria</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Gieser</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Przepiorka</surname><given-names>D.</given-names></name><etal/></person-group><article-title>FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia</article-title><source>Clin. Cancer Res.</source><year>2018</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2990</pub-id><pub-id pub-id-type="pmid">30541745</pub-id></element-citation></ref><ref id="B40-pharmaceutics-11-00110"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Tardi</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Dos Santos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liboiron</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Harasym</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Bermudes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>L.D.</given-names></name></person-group><article-title>Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts</article-title><source>Leuk. Res.</source><year>2010</year><volume>34</volume><fpage>1214</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2010.01.015</pub-id><pub-id pub-id-type="pmid">20138667</pub-id></element-citation></ref><ref id="B41-pharmaceutics-11-00110"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lancet</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Uy</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Medeiros</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Newell</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Hogge</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Strickland</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>S.R.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies</article-title><source>Blood</source><year>2017</year><volume>130</volume><fpage>4</fpage></element-citation></ref><ref id="B42-pharmaceutics-11-00110"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sethi</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>D.V.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>White</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>F.</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Stuart</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Muss</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Spurr</surname><given-names>C.L.</given-names></name></person-group><article-title>Pharmacokinetics of vincristine sulfate in adult cancer patients</article-title><source>Cancer Res.</source><year>1981</year><volume>41</volume><fpage>3551</fpage><lpage>3555</lpage><pub-id pub-id-type="pmid">7260915</pub-id></element-citation></ref><ref id="B43-pharmaceutics-11-00110"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>M.</given-names></name></person-group><article-title>Clinical pharmacokinetics of cytarabine formulations</article-title><source>Clin. Pharmacokinet.</source><year>2002</year><volume>41</volume><fpage>705</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.2165/00003088-200241100-00002</pub-id><pub-id pub-id-type="pmid">12162758</pub-id></element-citation></ref><ref id="B44-pharmaceutics-11-00110"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khatibi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>McCully</surname><given-names>C.</given-names></name><name name-style="western"><surname>Balis</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Poplack</surname><given-names>D.G.</given-names></name></person-group><article-title>Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam</article-title><source>Cancer Res.</source><year>1993</year><volume>53</volume><fpage>1596</fpage><lpage>1598</lpage><pub-id pub-id-type="pmid">8453629</pub-id></element-citation></ref><ref id="B45-pharmaceutics-11-00110"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phuphanich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maria</surname><given-names>B.</given-names></name><name name-style="western"><surname>Braeckman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chamberlain</surname><given-names>M.</given-names></name></person-group><article-title>A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study</article-title><source>J. Neurooncol.</source><year>2007</year><volume>81</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1007/s11060-006-9218-x</pub-id><pub-id pub-id-type="pmid">16941075</pub-id></element-citation></ref><ref id="B46-pharmaceutics-11-00110"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chatelut</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Cates</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kormanik</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Chamberlain</surname><given-names>M.C.</given-names></name></person-group><article-title>Extended CSF cytarabine exposure following intrathecal administration of DTC 101</article-title><source>J. Clin. Oncol.</source><year>1993</year><volume>11</volume><fpage>2186</fpage><lpage>2193</lpage><pub-id pub-id-type="doi">10.1200/JCO.1993.11.11.2186</pub-id><pub-id pub-id-type="pmid">8229133</pub-id></element-citation></ref><ref id="B47-pharmaceutics-11-00110"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glantz</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Jaeckle</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Chamberlain</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Phuphanich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Recht</surname><given-names>L.</given-names></name><name name-style="western"><surname>Swinnen</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Maria</surname><given-names>B.</given-names></name><name name-style="western"><surname>LaFollette</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schumann</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>B.F.</given-names></name><etal/></person-group><article-title>A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors</article-title><source>Clin. Cancer Res.</source><year>1999</year><volume>5</volume><fpage>3394</fpage><lpage>3402</lpage><pub-id pub-id-type="pmid">10589750</pub-id></element-citation></ref><ref id="B48-pharmaceutics-11-00110"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glantz</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>LaFollette</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jaeckle</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>W.</given-names></name><name name-style="western"><surname>Swinnen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rozental</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Phuphanich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Gutheil</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Batchelor</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis</article-title><source>J. Clin. Oncol.</source><year>1999</year><volume>17</volume><fpage>3110</fpage><lpage>3116</lpage><pub-id pub-id-type="doi">10.1200/JCO.1999.17.10.3110</pub-id><pub-id pub-id-type="pmid">10506606</pub-id></element-citation></ref><ref id="B49-pharmaceutics-11-00110"><label>49.</label><element-citation publication-type="journal"><article-title>FDA approves liposomal vincristine (Marqibo) for rare leukemia</article-title><source>Oncology (Williston Park)</source><year>2012</year><volume>26</volume><fpage>841</fpage><pub-id pub-id-type="pmid">23061340</pub-id></element-citation></ref><ref id="B50-pharmaceutics-11-00110"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pytlik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kozak</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chhanabhai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gascoyne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Deitcher</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>J.N.</given-names></name></person-group><article-title>Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study</article-title><source>Cancer</source><year>2009</year><volume>115</volume><fpage>3475</fpage><lpage>3482</lpage><pub-id pub-id-type="doi">10.1002/cncr.24359</pub-id><pub-id pub-id-type="pmid">19536896</pub-id></element-citation></ref><ref id="B51-pharmaceutics-11-00110"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Aulitzky</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ben Yehuda</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lister</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Selter</surname><given-names>K.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Stock</surname><given-names>W.</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Kantarjian</surname><given-names>H.</given-names></name></person-group><article-title>Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL)</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1200/jco.2010.28.15_suppl.6507</pub-id></element-citation></ref><ref id="B52-pharmaceutics-11-00110"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frampton</surname><given-names>J.E.</given-names></name></person-group><article-title>Mifamurtide: A review of its use in the treatment of osteosarcoma</article-title><source>Paediatr. Drugs.</source><year>2010</year><volume>12</volume><fpage>141</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.2165/11204910-000000000-00000</pub-id><pub-id pub-id-type="pmid">20481644</pub-id></element-citation></ref><ref id="B53-pharmaceutics-11-00110"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nardin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Labroquere</surname><given-names>K.</given-names></name><name name-style="western"><surname>Faure</surname><given-names>O.</given-names></name><name name-style="western"><surname>Abastado</surname><given-names>J.P.</given-names></name></person-group><article-title>Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma</article-title><source>Curr. Cancer Drug Targets</source><year>2006</year><volume>6</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.2174/156800906776056473</pub-id><pub-id pub-id-type="pmid">16529542</pub-id></element-citation></ref><ref id="B54-pharmaceutics-11-00110"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fogler</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Wade</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brundish</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Fidler</surname><given-names>I.J.</given-names></name></person-group><article-title>Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice</article-title><source>J. Immunol.</source><year>1985</year><volume>135</volume><fpage>1372</fpage><lpage>1377</lpage><pub-id pub-id-type="pmid">4008926</pub-id></element-citation></ref><ref id="B55-pharmaceutics-11-00110"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fogler</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Fidler</surname><given-names>I.J.</given-names></name></person-group><article-title>Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes</article-title><source>Int. J. Immunopharmacol.</source><year>1987</year><volume>9</volume><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/0192-0561(87)90088-9</pub-id><pub-id pub-id-type="pmid">3583507</pub-id></element-citation></ref><ref id="B56-pharmaceutics-11-00110"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fidler</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>N.O.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>I.R.</given-names></name></person-group><article-title>Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously</article-title><source>J. Biol. Response Mod.</source><year>1985</year><volume>4</volume><fpage>298</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">4020387</pub-id></element-citation></ref><ref id="B57-pharmaceutics-11-00110"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Shiah</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients</article-title><source>Cancer Chemother. Pharmacol.</source><year>2015</year><volume>75</volume><fpage>579</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1007/s00280-014-2671-x</pub-id><pub-id pub-id-type="pmid">25577133</pub-id><pub-id pub-id-type="pmcid">PMC4341010</pub-id></element-citation></ref><ref id="B58-pharmaceutics-11-00110"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang-Gillam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Bodoky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Jameson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Macarulla</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>J.F.</given-names></name><etal/></person-group><article-title>Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>545</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00986-1</pub-id><pub-id pub-id-type="pmid">26615328</pub-id></element-citation></ref><ref id="B59-pharmaceutics-11-00110"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laniado-Laborin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cabrales-Vargas</surname><given-names>M.N.</given-names></name></person-group><article-title>Amphotericin B: Side effects and toxicity</article-title><source>Rev. Iberoam. Micol.</source><year>2009</year><volume>26</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.riam.2009.06.003</pub-id><pub-id pub-id-type="pmid">19836985</pub-id></element-citation></ref><ref id="B60-pharmaceutics-11-00110"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stone</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Bicanic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Salim</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hope</surname><given-names>W.</given-names></name></person-group><article-title>Liposomal Amphotericin B (AmBisome((R))): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions</article-title><source>Drugs</source><year>2016</year><volume>76</volume><fpage>485</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1007/s40265-016-0538-7</pub-id><pub-id pub-id-type="pmid">26818726</pub-id><pub-id pub-id-type="pmcid">PMC4856207</pub-id></element-citation></ref><ref id="B61-pharmaceutics-11-00110"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bekersky</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Dressler</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Buell</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>T.J.</given-names></name></person-group><article-title>Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans</article-title><source>Antimicrob. Agents Chemother.</source><year>2002</year><volume>46</volume><fpage>828</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1128/AAC.46.3.828-833.2002</pub-id><pub-id pub-id-type="pmid">11850268</pub-id><pub-id pub-id-type="pmcid">PMC127462</pub-id></element-citation></ref><ref id="B62-pharmaceutics-11-00110"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leifer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chun</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Thaisz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Herr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nashed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>DiPetrillo</surname><given-names>K.</given-names></name></person-group><article-title>Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>915</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.00915</pub-id><pub-id pub-id-type="pmid">29867826</pub-id><pub-id pub-id-type="pmcid">PMC5964161</pub-id></element-citation></ref><ref id="B63-pharmaceutics-11-00110"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bovier</surname><given-names>P.A.</given-names></name></person-group><article-title>Epaxal: A virosomal vaccine to prevent hepatitis A infection</article-title><source>Expert Rev. Vaccines</source><year>2008</year><volume>7</volume><fpage>1141</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1586/14760584.7.8.1141</pub-id><pub-id pub-id-type="pmid">18844588</pub-id></element-citation></ref><ref id="B64-pharmaceutics-11-00110"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gluck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mischler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Finkel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Que</surname><given-names>J.U.</given-names></name><name name-style="western"><surname>Scarpa</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cryz</surname><given-names>S.J.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Immunogenicity of new virosome influenza vaccine in elderly people</article-title><source>Lancet</source><year>1994</year><volume>344</volume><fpage>160</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(94)92758-8</pub-id><pub-id pub-id-type="pmid">7912766</pub-id></element-citation></ref><ref id="B65-pharmaceutics-11-00110"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hartrick</surname><given-names>C.T.</given-names></name></person-group><article-title>Extended-release epidural morphine (DepoDur): An old drug with a new profile</article-title><source>Pain Pract.</source><year>2005</year><volume>5</volume><fpage>349</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1111/j.1533-2500.2005.00048.x</pub-id><pub-id pub-id-type="pmid">17177768</pub-id></element-citation></ref><ref id="B66-pharmaceutics-11-00110"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>T.</given-names></name><name name-style="western"><surname>Murdande</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name></person-group><article-title>Sustained-release morphine for epidural analgesia in rats</article-title><source>Anesthesiology</source><year>1996</year><volume>85</volume><fpage>331</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1097/00000542-199608000-00015</pub-id><pub-id pub-id-type="pmid">8712449</pub-id></element-citation></ref><ref id="B67-pharmaceutics-11-00110"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davidson</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Barenholz</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Haroutiunian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ginosar</surname><given-names>Y.</given-names></name></person-group><article-title>High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans</article-title><source>Anesth. Analg.</source><year>2010</year><volume>110</volume><fpage>1018</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1213/ANE.0b013e3181d26d2a</pub-id><pub-id pub-id-type="pmid">20357145</pub-id></element-citation></ref><ref id="B68-pharmaceutics-11-00110"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blumenkranz</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Bressler</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Bressler</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Donati</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fish</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Mones</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5</article-title><source>Arch. Ophthalmol.</source><year>2002</year><volume>120</volume><fpage>1307</fpage><lpage>1314</lpage><pub-id pub-id-type="pmid">12365909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archopht.120.10.1307</pub-id></element-citation></ref><ref id="B69-pharmaceutics-11-00110"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richter</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Waterfield</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Canaan</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>J.G.</given-names></name></person-group><article-title>Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model</article-title><source>Photochem. Photobiol.</source><year>1993</year><volume>57</volume><fpage>1000</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1111/j.1751-1097.1993.tb02962.x</pub-id><pub-id pub-id-type="pmid">8367528</pub-id></element-citation></ref><ref id="B70-pharmaceutics-11-00110"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laginha</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Verwoert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Charrois</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>T.M.</given-names></name></person-group><article-title>Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors</article-title><source>Clin. Cancer Res.</source><year>2005</year><volume>11</volume><fpage>6944</fpage><lpage>6949</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0343</pub-id><pub-id pub-id-type="pmid">16203786</pub-id></element-citation></ref><ref id="B71-pharmaceutics-11-00110"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabizon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tzemach</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bronstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Horowitz</surname><given-names>A.T.</given-names></name></person-group><article-title>Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models</article-title><source>J. Drug Target.</source><year>2002</year><volume>10</volume><fpage>539</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1080/1061186021000072447</pub-id><pub-id pub-id-type="pmid">12683721</pub-id></element-citation></ref><ref id="B72-pharmaceutics-11-00110"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Scherphof</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Kamps</surname><given-names>J.A.</given-names></name></person-group><article-title>Liposome opsonization</article-title><source>J. Liposome Res.</source><year>2005</year><volume>15</volume><fpage>109</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1081/LPR-64971</pub-id><pub-id pub-id-type="pmid">16194930</pub-id></element-citation></ref><ref id="B73-pharmaceutics-11-00110"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kiwada</surname><given-names>H.</given-names></name></person-group><article-title>Liposome clearance</article-title><source>Biosci. Rep.</source><year>2002</year><volume>22</volume><fpage>197</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1023/A:1020134521778</pub-id><pub-id pub-id-type="pmid">12428901</pub-id></element-citation></ref><ref id="B74-pharmaceutics-11-00110"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yingchoncharoen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kalinowski</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>D.R.</given-names></name></person-group><article-title>Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come</article-title><source>Pharmacol. Rev.</source><year>2016</year><volume>68</volume><fpage>701</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1124/pr.115.012070</pub-id><pub-id pub-id-type="pmid">27363439</pub-id><pub-id pub-id-type="pmcid">PMC4931871</pub-id></element-citation></ref><ref id="B75-pharmaceutics-11-00110"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Immordino</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Dosio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cattel</surname><given-names>L.</given-names></name></person-group><article-title>Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential</article-title><source>Int. J. Nanomed.</source><year>2006</year><volume>1</volume><fpage>297</fpage><lpage>315</lpage><pub-id pub-id-type="pmcid">PMC2426795</pub-id><pub-id pub-id-type="pmid">17717971</pub-id></element-citation></ref><ref id="B76-pharmaceutics-11-00110"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers</article-title><source>J. Clin. Oncol.</source><year>2013</year><volume>31</volume><fpage>2205</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.46.3653</pub-id><pub-id pub-id-type="pmid">23669226</pub-id><pub-id pub-id-type="pmcid">PMC3731977</pub-id></element-citation></ref><ref id="B77-pharmaceutics-11-00110"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stapleton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pintilie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jaffray</surname><given-names>D.A.</given-names></name></person-group><article-title>Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes</article-title><source>J. Control. Release</source><year>2013</year><volume>172</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2013.08.296</pub-id><pub-id pub-id-type="pmid">24021358</pub-id></element-citation></ref><ref id="B78-pharmaceutics-11-00110"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stapleton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Milosevic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tannock</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jaffray</surname><given-names>D.A.</given-names></name></person-group><article-title>The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation</article-title><source>J. Control. Release</source><year>2015</year><volume>211</volume><fpage>163</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.06.008</pub-id><pub-id pub-id-type="pmid">26070245</pub-id></element-citation></ref><ref id="B79-pharmaceutics-11-00110"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folkman</surname><given-names>J.</given-names></name></person-group><article-title>Tumor angiogenesis: Therapeutic implications</article-title><source>N. Engl. J. Med.</source><year>1971</year><volume>285</volume><fpage>1182</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1056/nejm197111182852108</pub-id><pub-id pub-id-type="pmid">4938153</pub-id></element-citation></ref><ref id="B80-pharmaceutics-11-00110"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorensen</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Emblem</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Polaskova</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ancukiewicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Ivy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Batchelor</surname><given-names>T.T.</given-names></name><etal/></person-group><article-title>Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion</article-title><source>Cancer Res.</source><year>2012</year><volume>72</volume><fpage>402</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-2464</pub-id><pub-id pub-id-type="pmid">22127927</pub-id><pub-id pub-id-type="pmcid">PMC3261301</pub-id></element-citation></ref><ref id="B81-pharmaceutics-11-00110"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorensen</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Batchelor</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Lahdenranta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ancukiewicz</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A &#8220;vascular normalization index&#8221; as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients</article-title><source>Cancer Res.</source><year>2009</year><volume>69</volume><fpage>5296</fpage><lpage>5300</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0814</pub-id><pub-id pub-id-type="pmid">19549889</pub-id><pub-id pub-id-type="pmcid">PMC2824172</pub-id></element-citation></ref><ref id="B82-pharmaceutics-11-00110"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy</article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1126/science.1104819</pub-id><pub-id pub-id-type="pmid">15637262</pub-id></element-citation></ref><ref id="B83-pharmaceutics-11-00110"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashizume</surname><given-names>H.</given-names></name><name name-style="western"><surname>Baluk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>McLean</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Thurston</surname><given-names>G.</given-names></name><name name-style="western"><surname>Roberge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>D.M.</given-names></name></person-group><article-title>Openings between defective endothelial cells explain tumor vessel leakiness</article-title><source>Am. J. Pathol.</source><year>2000</year><volume>156</volume><fpage>1363</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65006-7</pub-id><pub-id pub-id-type="pmid">10751361</pub-id><pub-id pub-id-type="pmcid">PMC1876882</pub-id></element-citation></ref><ref id="B84-pharmaceutics-11-00110"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Stylianopoulos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies</article-title><source>Annu. Rev. Chem. Biomol. Eng.</source><year>2011</year><volume>2</volume><fpage>281</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1146/annurev-chembioeng-061010-114300</pub-id><pub-id pub-id-type="pmid">22432620</pub-id></element-citation></ref><ref id="B85-pharmaceutics-11-00110"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Faix</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Schnitzer</surname><given-names>J.E.</given-names></name></person-group><article-title>Overcoming key biological barriers to cancer drug delivery and efficacy</article-title><source>J. Control. Release</source><year>2017</year><volume>267</volume><fpage>15</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.09.016</pub-id><pub-id pub-id-type="pmid">28917530</pub-id><pub-id pub-id-type="pmcid">PMC8756776</pub-id></element-citation></ref><ref id="B86-pharmaceutics-11-00110"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dellian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fukumura</surname><given-names>D.</given-names></name><name name-style="western"><surname>Leunig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size</article-title><source>Cancer Res.</source><year>1995</year><volume>55</volume><fpage>3752</fpage><lpage>3756</lpage><pub-id pub-id-type="pmid">7641188</pub-id></element-citation></ref><ref id="B87-pharmaceutics-11-00110"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ojha</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hennink</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Moonen</surname><given-names>C.T.W.</given-names></name><name name-style="western"><surname>Storm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kiessling</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lammers</surname><given-names>T.</given-names></name></person-group><article-title>Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors</article-title><source>Adv. Drug Deliv. Rev.</source><year>2017</year><volume>119</volume><fpage>44</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2017.07.007</pub-id><pub-id pub-id-type="pmid">28697952</pub-id><pub-id pub-id-type="pmcid">PMC5919100</pub-id></element-citation></ref><ref id="B88-pharmaceutics-11-00110"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milosevic</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Fyles</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pintilie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kavanagh</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Manchul</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Keane</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>R.P.</given-names></name></person-group><article-title>Interstitial fluid pressure in cervical carcinoma: Within tumor heterogeneity, and relation to oxygen tension</article-title><source>Cancer</source><year>1998</year><volume>82</volume><fpage>2418</fpage><lpage>2426</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0142(19980615)82:12&amp;#x0003c;2418::AID-CNCR16&amp;#x0003e;3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">9635535</pub-id></element-citation></ref><ref id="B89-pharmaceutics-11-00110"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heldin</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pietras</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ostman</surname><given-names>A.</given-names></name></person-group><article-title>High interstitial fluid pressure&#8212;An obstacle in cancer therapy</article-title><source>Nat. Rev. Cancer.</source><year>2004</year><volume>4</volume><fpage>806</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1038/nrc1456</pub-id><pub-id pub-id-type="pmid">15510161</pub-id></element-citation></ref><ref id="B90-pharmaceutics-11-00110"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netti</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Grodzinsky</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Role of extracellular matrix assembly in interstitial transport in solid tumors</article-title><source>Cancer Res.</source><year>2000</year><volume>60</volume><fpage>2497</fpage><lpage>2503</lpage><pub-id pub-id-type="pmid">10811131</pub-id></element-citation></ref><ref id="B91-pharmaceutics-11-00110"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies Cde</surname><given-names>L.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Pluen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells</article-title><source>Br. J. Cancer</source><year>2002</year><volume>86</volume><fpage>1639</fpage><lpage>1644</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600270</pub-id><pub-id pub-id-type="pmid">12085216</pub-id><pub-id pub-id-type="pmcid">PMC2746604</pub-id></element-citation></ref><ref id="B92-pharmaceutics-11-00110"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Leunig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Papahadjopoulos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft</article-title><source>Cancer Res.</source><year>1994</year><volume>54</volume><fpage>3352</fpage><lpage>3356</lpage><pub-id pub-id-type="pmid">8012948</pub-id></element-citation></ref><ref id="B93-pharmaceutics-11-00110"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kozin</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hicklin</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>3731</fpage><lpage>3736</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0074</pub-id><pub-id pub-id-type="pmid">15172975</pub-id></element-citation></ref><ref id="B94-pharmaceutics-11-00110"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKee</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Grandi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>W.</given-names></name><name name-style="western"><surname>Alexandrakis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Insin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Bawendi</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Breakefield</surname><given-names>X.O.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>2509</fpage><lpage>2513</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2242</pub-id><pub-id pub-id-type="pmid">16510565</pub-id></element-citation></ref><ref id="B95-pharmaceutics-11-00110"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Stylianopoulos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Popovic</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kamoun</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Bawendi</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Fukumura</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner</article-title><source>Nat. Nanotechnol.</source><year>2012</year><volume>7</volume><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/nnano.2012.45</pub-id><pub-id pub-id-type="pmid">22484912</pub-id><pub-id pub-id-type="pmcid">PMC3370066</pub-id></element-citation></ref><ref id="B96-pharmaceutics-11-00110"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duncan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>S.C.</given-names></name></person-group><article-title>Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges</article-title><source>Mol. Pharm.</source><year>2012</year><volume>9</volume><fpage>2380</fpage><lpage>2402</lpage><pub-id pub-id-type="doi">10.1021/mp300293n</pub-id><pub-id pub-id-type="pmid">22844998</pub-id></element-citation></ref><ref id="B97-pharmaceutics-11-00110"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirpotin</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Drummond</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shalaby</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>U.B.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Benz</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.W.</given-names></name></person-group><article-title>Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>6732</fpage><lpage>6740</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-4199</pub-id><pub-id pub-id-type="pmid">16818648</pub-id></element-citation></ref><ref id="B98-pharmaceutics-11-00110"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baru</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nahum</surname><given-names>O.</given-names></name><name name-style="western"><surname>Jaaro</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sha&#8217;anani</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nur</surname><given-names>I.</given-names></name></person-group><article-title>Lysosome-disrupting peptide increases the efficiency of in-vivo gene transfer by liposome-encapsulated DNA</article-title><source>J. Drug Target.</source><year>1998</year><volume>6</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.3109/10611869808997893</pub-id><pub-id pub-id-type="pmid">9888305</pub-id></element-citation></ref><ref id="B99-pharmaceutics-11-00110"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wientjes</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Au</surname><given-names>J.L.</given-names></name></person-group><article-title>Delivery of siRNA therapeutics: Barriers and carriers</article-title><source>AAPS J.</source><year>2010</year><volume>12</volume><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1208/s12248-010-9210-4</pub-id><pub-id pub-id-type="pmid">20544328</pub-id><pub-id pub-id-type="pmcid">PMC2977003</pub-id></element-citation></ref><ref id="B100-pharmaceutics-11-00110"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drummond</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Noble</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Kirpotin</surname><given-names>D.B.</given-names></name></person-group><article-title>Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development</article-title><source>J. Pharm. Sci.</source><year>2008</year><volume>97</volume><fpage>4696</fpage><lpage>4740</lpage><pub-id pub-id-type="doi">10.1002/jps.21358</pub-id><pub-id pub-id-type="pmid">18351638</pub-id></element-citation></ref><ref id="B101-pharmaceutics-11-00110"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ernsting</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.D.</given-names></name></person-group><article-title>Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles</article-title><source>J. Control. Release</source><year>2013</year><volume>172</volume><fpage>782</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2013.09.013</pub-id><pub-id pub-id-type="pmid">24075927</pub-id><pub-id pub-id-type="pmcid">PMC3891171</pub-id></element-citation></ref><ref id="B102-pharmaceutics-11-00110"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kanevsky</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Aronova</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Leapman</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Vo</surname><given-names>H.Q.</given-names></name></person-group><article-title>Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors</article-title><source>J. Transl. Med.</source><year>2009</year><volume>7</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-7-51</pub-id><pub-id pub-id-type="pmid">19549317</pub-id><pub-id pub-id-type="pmcid">PMC2706803</pub-id></element-citation></ref><ref id="B103-pharmaceutics-11-00110"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name></person-group><article-title>The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo</article-title><source>Adv. Drug Deliv. Rev.</source><year>2013</year><volume>65</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.10.002</pub-id><pub-id pub-id-type="pmid">23088862</pub-id></element-citation></ref><ref id="B104-pharmaceutics-11-00110"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zamboni</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Torchilin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Patri</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Hrkach</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Panaro</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Grodzinski</surname><given-names>P.</given-names></name></person-group><article-title>Best practices in cancer nanotechnology: Perspective from NCI nanotechnology alliance</article-title><source>Clin. Cancer Res.</source><year>2012</year><volume>18</volume><fpage>3229</fpage><lpage>3241</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2938</pub-id><pub-id pub-id-type="pmid">22669131</pub-id><pub-id pub-id-type="pmcid">PMC3916007</pub-id></element-citation></ref><ref id="B105-pharmaceutics-11-00110"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lammers</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kiessling</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hennink</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Storm</surname><given-names>G.</given-names></name></person-group><article-title>Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress</article-title><source>J. Control. Release</source><year>2012</year><volume>161</volume><fpage>175</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2011.09.063</pub-id><pub-id pub-id-type="pmid">21945285</pub-id></element-citation></ref><ref id="B106-pharmaceutics-11-00110"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caron</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Clewell</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dedrick</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tonda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Zamboni</surname><given-names>W.C.</given-names></name></person-group><article-title>Allometric scaling of pegylated liposomal anticancer drugs</article-title><source>J. Pharmacokinet. Pharmacodyn.</source><year>2011</year><volume>38</volume><fpage>653</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1007/s10928-011-9213-5</pub-id><pub-id pub-id-type="pmid">21863380</pub-id></element-citation></ref><ref id="B107-pharmaceutics-11-00110"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ait-Oudhia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mager</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Straubinger</surname><given-names>R.M.</given-names></name></person-group><article-title>Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology</article-title><source>Pharmaceutics.</source><year>2014</year><volume>6</volume><fpage>137</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.3390/pharmaceutics6010137</pub-id><pub-id pub-id-type="pmid">24647104</pub-id><pub-id pub-id-type="pmcid">PMC3978529</pub-id></element-citation></ref><ref id="B108-pharmaceutics-11-00110"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Zamboni</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Strychor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramalingam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Friedland</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Stoller</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Belani</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Maruca</surname><given-names>L.J.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies</article-title><source>J. Clin. Pharmacol.</source><year>2012</year><volume>52</volume><fpage>180</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1177/0091270010394851</pub-id><pub-id pub-id-type="pmid">21233302</pub-id></element-citation></ref><ref id="B109-pharmaceutics-11-00110"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Infante</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Keedy</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bendell</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zamboni</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kodaira</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2013</year><volume>69</volume><fpage>2073</fpage><lpage>2081</lpage><pub-id pub-id-type="doi">10.1007/s00228-013-1580-y</pub-id><pub-id pub-id-type="pmid">23989300</pub-id></element-citation></ref><ref id="B110-pharmaceutics-11-00110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Infante</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Keedy</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bendell</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kirschbrown</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Zamboni</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors</article-title><source>Int. J. Nanomed.</source><year>2015</year><volume>10</volume><fpage>1201</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.2147/IJN.S62911</pub-id><pub-id pub-id-type="pmid">25709442</pub-id><pub-id pub-id-type="pmcid">PMC4334335</pub-id></element-citation></ref><ref id="B111-pharmaceutics-11-00110"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rowland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.M.</given-names></name></person-group><article-title>Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions</article-title><source>Clin. Pharmacol. Ther.</source><year>2012</year><volume>92</volume><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/clpt.2012.68</pub-id><pub-id pub-id-type="pmid">22713733</pub-id></element-citation></ref><ref id="B112-pharmaceutics-11-00110"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grillo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brar</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Madabushi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.C.</given-names></name><etal/></person-group><article-title>Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review</article-title><source>Clin. Pharmacol. Ther.</source><year>2011</year><volume>89</volume><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1038/clpt.2010.298</pub-id><pub-id pub-id-type="pmid">21191381</pub-id></element-citation></ref><ref id="B113-pharmaceutics-11-00110"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peck</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>G.</given-names></name></person-group><article-title>Physiologically-based pharmacokinetics in drug development and regulatory science</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2011</year><volume>51</volume><fpage>45</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010510-100540</pub-id><pub-id pub-id-type="pmid">20854171</pub-id></element-citation></ref><ref id="B114-pharmaceutics-11-00110"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Abernethy</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zineh</surname><given-names>I.</given-names></name></person-group><article-title>The utility of modeling and simulation in drug development and regulatory review</article-title><source>J. Pharm. Sci.</source><year>2013</year><volume>102</volume><fpage>2912</fpage><lpage>2923</lpage><pub-id pub-id-type="doi">10.1002/jps.23570</pub-id><pub-id pub-id-type="pmid">23712632</pub-id></element-citation></ref><ref id="B115-pharmaceutics-11-00110"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Heimbach</surname><given-names>T.</given-names></name><name name-style="western"><surname>Parrott</surname><given-names>N.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Snoeys</surname><given-names>J.</given-names></name><name name-style="western"><surname>Upreti</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>S.D.</given-names></name></person-group><article-title>Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective</article-title><source>Clin. Pharmacol. Ther.</source><year>2015</year><volume>97</volume><fpage>247</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1002/cpt.37</pub-id><pub-id pub-id-type="pmid">25670209</pub-id></element-citation></ref><ref id="B116-pharmaceutics-11-00110"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Zineh</surname><given-names>I.</given-names></name></person-group><article-title>Physiologically based pharmacokinetic modeling: From regulatory science to regulatory policy</article-title><source>Clin. Pharmacol. Ther.</source><year>2014</year><volume>95</volume><fpage>478</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1038/clpt.2014.46</pub-id><pub-id pub-id-type="pmid">24747236</pub-id></element-citation></ref><ref id="B117-pharmaceutics-11-00110"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Al-Jamal</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Kostarelos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reineke</surname><given-names>J.</given-names></name></person-group><article-title>Physiologically based pharmacokinetic modeling of nanoparticles</article-title><source>ACS Nano</source><year>2010</year><volume>4</volume><fpage>6303</fpage><lpage>6317</lpage><pub-id pub-id-type="doi">10.1021/nn1018818</pub-id><pub-id pub-id-type="pmid">20945925</pub-id></element-citation></ref><ref id="B118-pharmaceutics-11-00110"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tsuchihashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Doi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kiwada</surname><given-names>H.</given-names></name></person-group><article-title>Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes</article-title><source>Adv. Drug Deliv. Rev.</source><year>1999</year><volume>40</volume><fpage>39</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(99)00039-3</pub-id><pub-id pub-id-type="pmid">10837779</pub-id></element-citation></ref><ref id="B119-pharmaceutics-11-00110"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Iida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Urakami</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tsuchihashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kiwada</surname><given-names>H.</given-names></name></person-group><article-title>Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling</article-title><source>J. Control. Release</source><year>1999</year><volume>61</volume><fpage>93</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(99)00110-8</pub-id><pub-id pub-id-type="pmid">10469906</pub-id></element-citation></ref><ref id="B120-pharmaceutics-11-00110"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendriks</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Klinz</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Geretti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Gaddy</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Espelin</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>U.B.</given-names></name><name name-style="western"><surname>Wickham</surname><given-names>T.J.</given-names></name></person-group><article-title>Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors</article-title><source>CPT Pharmacomet. Syst. Pharmacol.</source><year>2012</year><volume>1</volume><fpage>e15</fpage><pub-id pub-id-type="doi">10.1038/psp.2012.16</pub-id><pub-id pub-id-type="pmid">23835797</pub-id><pub-id pub-id-type="pmcid">PMC3600732</pub-id></element-citation></ref><ref id="B121-pharmaceutics-11-00110"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apgar</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Balasubramanian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Lasaro</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Miliard</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Quantitative Systems Pharmacology Model of hUGT1A1-modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler-Najjar Syndrome Type 1</article-title><source>CPT Pharmacomet. Syst. Pharmacol.</source><year>2018</year><volume>7</volume><fpage>404</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1002/psp4.12301</pub-id><pub-id pub-id-type="pmid">29637732</pub-id><pub-id pub-id-type="pmcid">PMC6391595</pub-id></element-citation></ref><ref id="B122-pharmaceutics-11-00110"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kagan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gershkovich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wasan</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Mager</surname><given-names>D.E.</given-names></name></person-group><article-title>Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition</article-title><source>Pharm. Res.</source><year>2014</year><volume>31</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/s11095-013-1127-z</pub-id><pub-id pub-id-type="pmid">23793994</pub-id></element-citation></ref><ref id="B123-pharmaceutics-11-00110"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khawar</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kuh</surname><given-names>H.J.</given-names></name></person-group><article-title>Improving drug delivery to solid tumors: Priming the tumor microenvironment</article-title><source>J. Control. Release</source><year>2015</year><volume>201</volume><fpage>78</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.12.018</pub-id><pub-id pub-id-type="pmid">25526702</pub-id></element-citation></ref><ref id="B124-pharmaceutics-11-00110"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stapleton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Milosevic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dunne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jaffray</surname><given-names>D.A.</given-names></name></person-group><article-title>A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e81157</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0081157</pub-id><pub-id pub-id-type="pmid">24312530</pub-id><pub-id pub-id-type="pmcid">PMC3846845</pub-id></element-citation></ref><ref id="B125-pharmaceutics-11-00110"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frieboes</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lowengrub</surname><given-names>J.</given-names></name><name name-style="western"><surname>Decuzzi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cristini</surname><given-names>V.</given-names></name></person-group><article-title>A computational model for predicting nanoparticle accumulation in tumor vasculature</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e56876</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0056876</pub-id><pub-id pub-id-type="pmid">23468887</pub-id><pub-id pub-id-type="pmcid">PMC3585411</pub-id></element-citation></ref><ref id="B126-pharmaceutics-11-00110"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troendle</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Searson</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Ulmschneider</surname><given-names>M.B.</given-names></name></person-group><article-title>Predicting drug delivery efficiency into tumor tissues through molecular simulation of transport in complex vascular networks</article-title><source>J. Control. Release</source><year>2018</year><volume>292</volume><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.11.010</pub-id><pub-id pub-id-type="pmid">30415016</pub-id><pub-id pub-id-type="pmcid">PMC10131895</pub-id></element-citation></ref><ref id="B127-pharmaceutics-11-00110"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macklin</surname><given-names>P.</given-names></name><name name-style="western"><surname>McDougall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Chaplain</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cristini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lowengrub</surname><given-names>J.</given-names></name></person-group><article-title>Multiscale modelling and nonlinear simulation of vascular tumour growth</article-title><source>J. Math. Biol.</source><year>2009</year><volume>58</volume><fpage>765</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1007/s00285-008-0216-9</pub-id><pub-id pub-id-type="pmid">18781303</pub-id><pub-id pub-id-type="pmcid">PMC3037282</pub-id></element-citation></ref><ref id="B128-pharmaceutics-11-00110"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lowengrub</surname><given-names>J.</given-names></name><name name-style="western"><surname>Decuzzi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Frieboes</surname><given-names>H.B.</given-names></name></person-group><article-title>Computational Modeling of Tumor Response to Drug Release from Vasculature-Bound Nanoparticles</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0144888</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0144888</pub-id><pub-id pub-id-type="pmid">26660469</pub-id><pub-id pub-id-type="pmcid">PMC4682796</pub-id></element-citation></ref><ref id="B129-pharmaceutics-11-00110"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stylianopoulos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Soteriou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fukumura</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Cationic nanoparticles have superior transvascular flux into solid tumors: Insights from a mathematical model</article-title><source>Ann. Biomed. Eng.</source><year>2013</year><volume>41</volume><fpage>68</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1007/s10439-012-0630-4</pub-id><pub-id pub-id-type="pmid">22855118</pub-id><pub-id pub-id-type="pmcid">PMC3886728</pub-id></element-citation></ref><ref id="B130-pharmaceutics-11-00110"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stylianopoulos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Economides</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Baish</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Fukumura</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Towards Optimal Design of Cancer Nanomedicines: Multi-stage Nanoparticles for the Treatment of Solid Tumors</article-title><source>Ann. Biomed. Eng.</source><year>2015</year><volume>43</volume><fpage>2291</fpage><lpage>2300</lpage><pub-id pub-id-type="doi">10.1007/s10439-015-1276-9</pub-id><pub-id pub-id-type="pmid">25670323</pub-id><pub-id pub-id-type="pmcid">PMC4519365</pub-id></element-citation></ref><ref id="B131-pharmaceutics-11-00110"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stylianopoulos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Combining two strategies to improve perfusion and drug delivery in solid tumors</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>18632</fpage><lpage>18637</lpage><pub-id pub-id-type="doi">10.1073/pnas.1318415110</pub-id><pub-id pub-id-type="pmid">24167277</pub-id><pub-id pub-id-type="pmcid">PMC3832007</pub-id></element-citation></ref><ref id="B132-pharmaceutics-11-00110"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirtane</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Panyam</surname><given-names>J.</given-names></name></person-group><article-title>A pharmacokinetic model for quantifying the effect of vascular permeability on the choice of drug carrier: a framework for personalized nanomedicine</article-title><source>J. Pharm. Sci.</source><year>2015</year><volume>104</volume><fpage>1174</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1002/jps.24302</pub-id><pub-id pub-id-type="pmid">25583443</pub-id></element-citation></ref><ref id="B133-pharmaceutics-11-00110"><label>133.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>FDA</collab></person-group><article-title>Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation and Application of In Vitro/In Vivo Correlations</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/downloads/drugs/guidances/ucm070239.pdf">https://www.fda.gov/downloads/drugs/guidances/ucm070239.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-01-15">(accessed on 15 January 2019)</date-in-citation></element-citation></ref><ref id="B134-pharmaceutics-11-00110"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shabbits</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>L.D.</given-names></name></person-group><article-title>Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems</article-title><source>J. Control. Release</source><year>2002</year><volume>84</volume><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/S0168-3659(02)00294-8</pub-id><pub-id pub-id-type="pmid">12468219</pub-id></element-citation></ref><ref id="B135-pharmaceutics-11-00110"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>D.J.</given-names></name></person-group><article-title>A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes</article-title><source>Int. J. Pharm.</source><year>2012</year><volume>426</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2012.01.030</pub-id><pub-id pub-id-type="pmid">22301423</pub-id></element-citation></ref><ref id="B136-pharmaceutics-11-00110"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crielaard</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Yousefi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schillemans</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Vermehren</surname><given-names>C.</given-names></name><name name-style="western"><surname>Buyens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Braeckmans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lammers</surname><given-names>T.</given-names></name><name name-style="western"><surname>Storm</surname><given-names>G.</given-names></name></person-group><article-title>An in vitro assay based on surface plasmon resonance to predict the in vivo circulation kinetics of liposomes</article-title><source>J. Control. Release</source><year>2011</year><volume>156</volume><fpage>307</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2011.07.023</pub-id><pub-id pub-id-type="pmid">21803084</pub-id></element-citation></ref><ref id="B137-pharmaceutics-11-00110"><label>137.</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name></person-group><article-title>Physiologically based pharmacokinetic platform to quantify the influence of nano&#8211;bio interactions on the biodistribution of liposomal drug (In preparation)</article-title></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceutics-11-00110-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Multiscale physiological barriers to the targeted distribution of liposomal drugs. The dose fraction change was obtained from references [<xref rid="B70-pharmaceutics-11-00110" ref-type="bibr">70</xref>,<xref rid="B71-pharmaceutics-11-00110" ref-type="bibr">71</xref>]. MPS&#8212;mononuclear phagocyte system; IFP&#8212;interstitial fluid pressure; ECM&#8212;extracellular matrix.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-11-00110-g001.jpg"/></fig><fig id="pharmaceutics-11-00110-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>A general PBPK model diagram for liposomal drugs. (<bold>A</bold>) A generic dual-layer PBPK model. The black solid line represents the blood flow and the blue dashed line depicts the lymph flow. (<bold>B</bold>) A tumor tissue compartment model for liposomes. The distribution from blood to drug target involves liposome extravasation, diffusion of the released payload between blood and interstitial fluid, direct or tissue-associated macrophage-mediated release of the payload, tumor cell endocytosis of liposomes, intracellular release of the payload in tumor cells, target binding, and recycling of intact liposomes through lymph back to the blood. Q&#8212;blood flow; CL<sub>r</sub>&#8212;renal clearance; CL<sub>h</sub>&#8212;hepatic clearance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-11-00110-g002.jpg"/></fig><table-wrap id="pharmaceutics-11-00110-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-11-00110-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of the approved liposomal drugs for use in humans by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Product</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapeutic Area</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year of Approval</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PK&#8211;PD Profiles</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DaunoXome<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daunorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1996</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolonged retention, increased target distribution, equivalent efficacy, and reduced toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DepoCyt<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytarabine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1999</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolonged tumor exposure to cytotoxic concentration, increased response rate, and reduced toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxil<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolonged retention, increased target distribution, equivalent efficacy, and reduced toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipodox<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolonged retention, increased target distribution, equivalent efficacy, and reduced toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myocet<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolonged retention, increased target distribution, equivalent efficacy, and reduced toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Marqibo<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vincristine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolonged retention, increased target distribution, superior efficacy, and reduced toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vyxeos<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Daunorubicin-cytarabine (1:5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased targeted exposure of daunorubicin and cytarabine in a fixed ratio, superior efficacy, and comparable toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Onivyde<sup>TM</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Irinotecan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolonged retention and increased exposure of the bioactive metabolite of irinotecan (SN-38), superior efficacy, and reduced toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mepact<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mifamurtide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolonged and increased retention in target, superior efficacy, and reduced toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ambisome<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amphotericin B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1997</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Releases the drug only when the liposome binds to the fungus and significant reduction in toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arikayce<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amikacin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased target distribution, superior efficacy, and comparable toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflexal<sup>&#174;</sup> V</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flu vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1997</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Superior immune response.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epaxal<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatitis A vaccine (synthetic lipids, influenza proteins, hepatitis A antigen)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1994</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher tolerability and reduced toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DepoDur<sup>TM</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morphine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Analgesics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolonged retention, reduced peak concentration, superior efficacy, and reduced toxicity. </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exparel<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bupivacaine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Analgesics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolonged retention, reduced peak concentration, superior efficacy, and reduced toxicity.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Visudyne<sup>&#174;</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Verteporfin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Photodynamic therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Equivalent clearance, slightly increased tissue distribution, and reduced toxicity.</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceutics-11-00110-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-11-00110-t002_Table 2</object-id><label>Table 2</label><caption><p>Pharmacokinetic&#8211;Pharmacodynamic (PK&#8211;PD) modeling systems in liposomal drug delivery.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Approach</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mathematical Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mathematical Model of the Rest of the Body</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drugs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Notes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Simplified physiologically-based pharmacokinetic (PBPK) model<break/>Simplified PBPK model<break/>Simplified PBPK model</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor was divided into capillary, interstitial and tumor cell sub-compartments.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1-compartment PK model for liposome and 2-compartment PK model for drug.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomal retention in tumors and the local release rate were identified to play pivotal roles in antitumor efficacy. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-pharmaceutics-11-00110" ref-type="bibr">118</xref>,<xref rid="B119-pharmaceutics-11-00110" ref-type="bibr">119</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor was divided into capillary, interstitial, tumor cell and nucleus sub-compartments. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1-compartment PK model for liposome and2-compartment PK model for drug.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The detailed drug transport into and out of the cell, drug-target association and dissociation, and liposome uptake and release in tumor cells were described.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B120-pharmaceutics-11-00110" ref-type="bibr">120</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver hepatocyte compartment with endosomal and cytoplastic compartments.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma compartment.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hUGT1A1-modRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Endocytosis, release and transcription processes were described. After translated to humans, this model was used to estimate the first-in-human dose.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-pharmaceutics-11-00110" ref-type="bibr">121</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Whole-body PBPK model</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma and tissue (liver, spleen, kidneys, gut, lungs, heart and others) compartments. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amphotericin B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The first whole-body PBPK model described the disposition of both liposome and drug simultaneously. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B122-pharmaceutics-11-00110" ref-type="bibr">122</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Model with spatiotemporal characterization<break/>Model with spatiotemporal characterization</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The combination of tumor growth, angiogenesis, oxygen transport, nanoparticle transport and antitumor effect models. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The physiological properties of the tumor were considered. The model described the interactions between tumor progression and liposome disposition.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B125-pharmaceutics-11-00110" ref-type="bibr">125</xref>,<xref rid="B127-pharmaceutics-11-00110" ref-type="bibr">127</xref>,<xref rid="B128-pharmaceutics-11-00110" ref-type="bibr">128</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor vascular network and nanoparticle transport model. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">/</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tumor blood vessel properties were simulated in this model. The interactions between the liposome and blood vessel were simulated to optimize the particle properties. </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-pharmaceutics-11-00110" ref-type="bibr">129</xref>,<xref rid="B130-pharmaceutics-11-00110" ref-type="bibr">130</xref>,<xref rid="B131-pharmaceutics-11-00110" ref-type="bibr">131</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model with in vitro&#8212;in vivo correlation (IVIVC) </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Using in vitro studies to determine the model parameters and replace in vivo study in liposome optimization study.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Plasma and tissues compartments.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doxorubicin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposome property&#8211;disposition relationships were established to facilitate liposome optimization.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B137-pharmaceutics-11-00110" ref-type="bibr">137</xref>]</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>